CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: bexarotene
Accession: CHEBI:50859
browse the term
Definition: A retinoid that has formula C24H28O2.
Synonyms: exact_synonym: 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid
related_synonym: Formula=C24H28O2; InChI=1S/C24H28O2/c1-15-13-20-21(24(5,6)12-11-23(20,3)4)14-19(15)16(2)17-7-9-18(10-8-17)22(25)26/h7-10,13-14H,2,11-12H2,1,3-6H3,(H,25,26); InChIKey=NAVMQTYZDKMPEU-UHFFFAOYSA-N; SMILES=Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C; bexaroteno; bexarotenum; p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
xref: CAS:153559-49-0; DrugBank:DB00307; Drug_Central:361; KEGG:D03106
xref_mesh: MESH:C095105
xref: Patent:US5466861; Patent:WO9321146; Wikipedia:Bexarotene
G
A1bg
alpha-1-B glycoprotein
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of A1BG mRNA
CTD
PMID:17630414
NCBI chr 7:92,493,934...92,498,460
Ensembl chr 7:92,494,372...92,498,097
G
Abca1
ATP binding cassette subfamily A member 1
increases expression multiple interactions increases expression
ISO
bexarotene results in increased expression of ABCA1; bexarotene results in increased expression of ABCA1 mRNA diazepinylbenzoic acid inhibits the reaction [bexarotene results in increased expression of ABCA1 mRNA] [bexarotene co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein bexarotene increases expression of Abca1 protein in mouse cerebral cortex bexarotene increases expression of abca1 protein in mouse hippocampus
CTD RGD
PMID:21622945 PMID:25932594 PMID:26688581 PMID:25217640
RGD:11056803 , RGD:21408550
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
G
Abcb11
ATP binding cassette subfamily B member 11
increases expression
EXP
bexarotene results in increased expression of ABCB11 mRNA
CTD
PMID:16648578
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
G
Abcd3
ATP binding cassette subfamily D member 3
increases expression
EXP
bexarotene results in increased expression of ABCD3 mRNA
CTD
PMID:16648578 PMID:23292798
NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020
G
Acaa1a
acetyl-CoA acyltransferase 1A
increases expression multiple interactions
EXP
bexarotene results in increased expression of ACAA1 mRNA; bexarotene results in increased expression of ACAA1A mRNA [Tamoxifen co-treated with bexarotene] results in increased expression of ACAA1 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624
G
Acaca
acetyl-CoA carboxylase alpha
increases expression
EXP
bexarotene results in increased expression of ACACA mRNA
CTD
PMID:23292798
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
G
Acadm
acyl-CoA dehydrogenase medium chain
increases expression
EXP
bexarotene results in increased expression of ACADM mRNA
CTD
PMID:23292798
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
G
Acat1
acetyl-CoA acetyltransferase 1
increases expression multiple interactions
EXP
bexarotene results in increased expression of ACAT1 mRNA [Tamoxifen co-treated with bexarotene] results in increased expression of ACAT1 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855
G
Ache
acetylcholinesterase
decreases expression
EXP
bexarotene results in decreased expression of ACHE mRNA
CTD
PMID:16648578
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
G
Acot1
acyl-CoA thioesterase 1
increases expression multiple interactions
EXP
Bexarotene results in increased expression of ACOT1 mRNA [Tamoxifen co-treated with Bexarotene] results in increased expression of ACOT1 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
G
Acot2
acyl-CoA thioesterase 2
increases expression
EXP
bexarotene results in increased expression of ACOT2 mRNA
CTD
PMID:16648578
NCBI chr 6:103,611,738...103,619,404
Ensembl chr 6:103,611,544...103,619,245
G
Acox1
acyl-CoA oxidase 1
increases expression
EXP
bexarotene results in increased expression of ACOX1 mRNA
CTD
PMID:16648578 PMID:23292798
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
G
Acsl1
acyl-CoA synthetase long-chain family member 1
increases expression
EXP
bexarotene results in increased expression of ACSL1 mRNA
CTD
PMID:23292798
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
G
Acsl5
acyl-CoA synthetase long-chain family member 5
increases expression
EXP
bexarotene results in increased expression of ACSL5 mRNA
CTD
PMID:23292798
NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
G
Acsm3
acyl-CoA synthetase medium-chain family member 3
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of SAH mRNA
CTD
PMID:17630414
NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184
G
Acta2
actin alpha 2, smooth muscle
increases expression
EXP
bexarotene results in increased expression of ACTA2 mRNA
CTD
PMID:16648578
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
G
Actc1
actin, alpha, cardiac muscle 1
increases expression
EXP
bexarotene results in increased expression of ACTC1 mRNA
CTD
PMID:16648578
NCBI chr 3:100,811,987...100,817,523
Ensembl chr 3:100,811,987...100,817,523
G
Actg1
actin, gamma 1
increases expression
EXP
bexarotene results in increased expression of ACTG1 mRNA
CTD
PMID:16648578
NCBI chr10:105,619,738...105,622,587
Ensembl chr10:105,619,737...105,624,232 Ensembl chr 3:105,619,737...105,624,232
G
Acvr2b
activin A receptor type 2B
increases expression
EXP
bexarotene results in increased expression of ACVR2B mRNA
CTD
PMID:16648578
NCBI chr 8:119,138,901...119,178,477
Ensembl chr 8:119,138,812...119,170,458
G
Adcy6
adenylate cyclase 6
decreases expression
EXP
bexarotene results in decreased expression of ADCY6 mRNA
CTD
PMID:16648578
NCBI chr 7:129,742,827...129,763,922
Ensembl chr 7:129,742,838...129,763,754
G
Add3
adducin 3
increases expression
ISO
bexarotene results in increased expression of ADD3 mRNA
CTD
PMID:17178900
NCBI chr 1:252,147,341...252,255,126
Ensembl chr 1:252,147,386...252,255,124
G
Adh4
alcohol dehydrogenase 4 (class II), pi polypeptide
increases expression
EXP
bexarotene results in increased expression of ADH4 mRNA
CTD
PMID:17630414
NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591
G
Adig
adipogenin
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of ADIG mRNA
CTD
PMID:17630414
NCBI chr 3:147,155,079...147,160,412
Ensembl chr 3:147,154,097...147,160,490 Ensembl chr 3:147,154,097...147,160,490
G
Adra1b
adrenoceptor alpha 1B
decreases expression
EXP
bexarotene results in decreased expression of ADRA1B mRNA
CTD
PMID:16648578
NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919
G
Adrb2
adrenoceptor beta 2
decreases expression
ISO
bexarotene results in decreased expression of ADRB2 mRNA
CTD
PMID:17178900
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
G
Agxt
alanine--glyoxylate aminotransferase
increases expression
EXP
bexarotene results in increased expression of AGXT mRNA
CTD
PMID:16648578
NCBI chr 9:93,675,384...93,685,337
Ensembl chr 9:93,675,384...93,685,336
G
Ahsg
alpha-2-HS-glycoprotein
decreases expression
EXP
bexarotene results in decreased expression of AHSG mRNA
CTD
PMID:16648578
NCBI chr11:78,121,388...78,127,998
Ensembl chr11:78,117,918...78,145,999
G
Akap12
A-kinase anchoring protein 12
increases expression
EXP
bexarotene results in increased expression of AKAP12 mRNA
CTD
PMID:16648578
NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886
G
Akr1c1
aldo-keto reductase family 1, member C1
increases expression
ISO
Bexarotene results in increased expression of AKR1C1 mRNA
CTD
PMID:17178900
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
G
Akr1c3
aldo-keto reductase family 1, member C3
increases expression
ISO
bexarotene results in increased expression of AKR1C3 mRNA
CTD
PMID:17178900
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
G
Aldh3a2
aldehyde dehydrogenase 3 family, member A2
decreases expression
EXP
bexarotene results in decreased expression of ALDH3A2 mRNA
CTD
PMID:16648578
NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281
G
Aldoa
aldolase, fructose-bisphosphate A
increases expression
EXP
Bexarotene results in increased expression of ALDOA mRNA
CTD
PMID:16648578
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
G
Aldob
aldolase, fructose-bisphosphate B
decreases expression
EXP
bexarotene results in decreased expression of ALDOB mRNA
CTD
PMID:16648578
NCBI chr 5:63,889,045...63,902,086
Ensembl chr 5:63,889,046...63,902,116
G
Aldoc
aldolase, fructose-bisphosphate C
increases expression
EXP
bexarotene results in increased expression of ALDOC mRNA
CTD
PMID:16648578
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
G
Alpl
alkaline phosphatase, biomineralization associated
increases expression
EXP
bexarotene results in increased expression of ALPL mRNA
CTD
PMID:16648578
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
G
Amotl2
angiomotin like 2
decreases expression
ISO
bexarotene results in decreased expression of AMOTL2 mRNA
CTD
PMID:17178900
NCBI chr 8:103,303,368...103,319,161
Ensembl chr 8:103,302,992...103,318,910
G
Angptl4
angiopoietin-like 4
increases expression
ISO
bexarotene results in increased expression of ANGPTL4 mRNA
CTD
PMID:21622945
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
G
Ank3
ankyrin 3
decreases expression
EXP
bexarotene results in decreased expression of ANK3 mRNA
CTD
PMID:16648578
NCBI chr20:18,602,267...19,225,831
Ensembl chr20:18,602,786...19,086,300
G
Anxa3
annexin A3
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of ANXA3 mRNA
CTD
PMID:17630414
NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617
G
Aplp2
amyloid beta precursor like protein 2
increases expression
EXP
bexarotene results in increased expression of APLP2 mRNA
CTD
PMID:16648578
NCBI chr 8:29,599,230...29,662,311
Ensembl chr 8:29,599,230...29,661,855
G
Apoa2
apolipoprotein A2
multiple interactions decreases expression increases expression
ISO EXP
RXRA promotes the reaction [bexarotene results in increased expression of APOA2 mRNA] bexarotene results in decreased expression of APOA2 mRNA
CTD
PMID:8668150 PMID:16648578
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
G
Apob
apolipoprotein B
decreases expression
EXP
bexarotene results in decreased expression of APOB mRNA
CTD
PMID:16648578
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
G
Apoc1
apolipoprotein C1
decreases expression
EXP
bexarotene results in decreased expression of APOC1 mRNA
CTD
PMID:16648578
NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375
G
Apoc3
apolipoprotein C3
decreases expression
EXP
bexarotene results in decreased expression of APOC3 mRNA
CTD
PMID:16648578
NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583
G
Apod
apolipoprotein D
increases expression
ISO
bexarotene results in increased expression of APOD mRNA
CTD
PMID:17849452
NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305
G
App
amyloid beta precursor protein
increases expression
EXP
bexarotene results in increased expression of APP mRNA
CTD
PMID:16648578
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
G
Aqp7
aquaporin 7
multiple interactions decreases expression
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of AQP7 mRNA bexarotene results in decreased expression of AQP7 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr 5:56,171,649...56,186,642
Ensembl chr 5:56,172,519...56,186,642
G
Ar
androgen receptor
multiple interactions increases expression
ISO EXP
bexarotene binds to and results in decreased activity of AR protein bexarotene results in increased expression of AR mRNA
CTD
PMID:16648578 PMID:25752796
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
G
Arf1
ADP-ribosylation factor 1
increases expression
EXP
bexarotene results in increased expression of ARF1 mRNA
CTD
PMID:16648578
NCBI chr10:43,997,983...44,014,461
Ensembl chr10:43,997,986...44,014,434
G
Arg1
arginase 1
decreases expression
EXP
bexarotene results in decreased expression of ARG1 mRNA
CTD
PMID:16648578
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
G
Arl6ip5
ADP-ribosylation factor like GTPase 6 interacting protein 5
increases expression
ISO
bexarotene results in increased expression of ARL6IP5 mRNA
CTD
PMID:17178900
NCBI chr 4:129,810,650...129,838,628
Ensembl chr 4:129,810,645...129,838,608
G
Arpc1b
actin related protein 2/3 complex, subunit 1B
increases expression
EXP
bexarotene results in increased expression of ARPC1B mRNA
CTD
PMID:16648578
NCBI chr12:9,482,176...9,495,772
Ensembl chr12:9,480,831...9,495,747
G
Ascl1
achaete-scute family bHLH transcription factor 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of ASCL1 mRNA
CTD
PMID:17630414
NCBI chr 7:21,903,136...21,906,003
Ensembl chr 7:21,903,126...21,905,993
G
Asgr1
asialoglycoprotein receptor 1
increases expression
EXP
bexarotene results in increased expression of ASGR1 mRNA
CTD
PMID:16648578
NCBI chr10:54,775,727...54,779,642
Ensembl chr10:54,776,024...54,779,631
G
Asns
asparagine synthetase (glutamine-hydrolyzing)
decreases expression
ISO
bexarotene results in decreased expression of ASNS mRNA
CTD
PMID:17178900
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
G
Atm
ATM serine/threonine kinase
increases activity
ISO
bexarotene results in increased activity of ATM protein
CTD
PMID:19067706
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
G
Atp1a1
ATPase Na+/K+ transporting subunit alpha 1
increases expression
EXP
bexarotene results in increased expression of ATP1A1 mRNA
CTD
PMID:16648578
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
G
Atp1b1
ATPase Na+/K+ transporting subunit beta 1
decreases expression
EXP
bexarotene results in decreased expression of ATP1B1 mRNA
CTD
PMID:16648578
NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
G
Atp4a
ATPase H+/K+ transporting subunit alpha
increases expression
EXP
bexarotene results in increased expression of ATP4A mRNA
CTD
PMID:16648578
NCBI chr 1:85,961,607...85,974,972
Ensembl chr 1:85,961,708...85,974,844
G
Atp5f1d
ATP synthase F1 subunit delta
increases expression
EXP
bexarotene results in increased expression of ATP5F1D mRNA
CTD
PMID:16648578
NCBI chr 7:9,560,604...9,565,919
Ensembl chr 7:9,560,608...9,565,929
G
Atp6v0c
ATPase H+ transporting V0 subunit C
increases expression
EXP
bexarotene results in increased expression of ATP6V0C mRNA
CTD
PMID:16648578
NCBI chr10:13,196,204...13,202,580
Ensembl chr10:13,196,204...13,201,500
G
Bax
BCL2 associated X, apoptosis regulator
multiple interactions
ISO
bexarotene results in increased expression of and results in increased activity of BAX protein
CTD
PMID:19067706
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
G
Bbs2
Bardet-Biedl syndrome 2
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of BBS2 mRNA
CTD
PMID:17630414
NCBI chr19:10,909,653...10,944,998
Ensembl chr19:10,909,619...10,944,993
G
Bglap
bone gamma-carboxyglutamate protein
multiple interactions
ISO
bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]
CTD
PMID:25932594
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
G
Bhlhe41
basic helix-loop-helix family, member e41
decreases expression
EXP
bexarotene results in decreased expression of BHLHE41 mRNA
CTD
PMID:16648578
NCBI chr 4:178,834,264...178,838,618
Ensembl chr 4:178,834,271...178,838,468
G
Birc5
baculoviral IAP repeat-containing 5
decreases expression
ISO
bexarotene results in decreased expression of BIRC5 mRNA bexarotene results in decreased expression of BIRC5 protein
CTD
PMID:17849452 PMID:19067706
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
G
Bmp2
bone morphogenetic protein 2
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of BMP2 mRNA
CTD
PMID:17630414
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
G
Bnip2
BCL2 interacting protein 2
decreases expression
ISO
bexarotene results in decreased expression of BNIP2 mRNA
CTD
PMID:17178900
NCBI chr 8:70,640,436...70,661,782
Ensembl chr 8:70,640,445...70,675,590
G
Btg2
BTG anti-proliferation factor 2
decreases expression
EXP
bexarotene results in decreased expression of BTG2 mRNA
CTD
PMID:16648578
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
G
C1qb
complement C1q B chain
multiple interactions increases expression
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of C1QB mRNA bexarotene results in increased expression of C1QB mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407
G
C3
complement C3
decreases expression
EXP
bexarotene results in decreased expression of C3 mRNA
CTD
PMID:16648578
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
G
C4bpa
complement component 4 binding protein, alpha
decreases expression
EXP
bexarotene results in decreased expression of C4BPA mRNA
CTD
PMID:16648578
NCBI chr13:42,075,715...42,111,205
Ensembl chr13:42,075,717...42,111,205
G
Cacna2d3
calcium voltage-gated channel auxiliary subunit alpha2delta 3
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of CACNA2D3 mRNA
CTD
PMID:17630414
NCBI chr16:4,098,439...4,912,498
Ensembl chr16:4,098,445...4,912,351
G
Calr
calreticulin
increases expression
EXP
bexarotene results in increased expression of CALR mRNA
CTD
PMID:16648578
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
G
Camk2g
calcium/calmodulin-dependent protein kinase II gamma
increases expression
EXP
bexarotene results in increased expression of CAMK2G mRNA
CTD
PMID:16648578
NCBI chr15:3,504,017...3,563,050
Ensembl chr15:3,504,085...3,563,050
G
Canx
calnexin
increases expression
EXP
bexarotene results in increased expression of CANX mRNA
CTD
PMID:16648578
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
G
Casp3
caspase 3
decreases expression
ISO
bexarotene results in decreased expression of CASP3 mRNA
CTD
PMID:17849452
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
G
Casp6
caspase 6
decreases expression
EXP
bexarotene results in decreased expression of CASP6 mRNA
CTD
PMID:16648578
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
G
Cbr1
carbonyl reductase 1
increases expression
EXP
Bexarotene results in increased expression of CBR1 mRNA
CTD
PMID:16648578
NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
G
Ccl11
C-C motif chemokine ligand 11
decreases expression
EXP
bexarotene results in decreased expression of CCL11 mRNA
CTD
PMID:16648578
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
G
Ccn1
cellular communication network factor 1
decreases expression
ISO
Bexarotene results in decreased expression of CCN1 mRNA
CTD
PMID:17178900
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
G
Ccnb1
cyclin B1
decreases expression
ISO
bexarotene results in decreased expression of CCNB1 protein
CTD
PMID:19067706
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
G
Ccnb2
cyclin B2
decreases expression
ISO
bexarotene results in decreased expression of CCNB2 mRNA
CTD
PMID:17849452
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
G
Ccnd1
cyclin D1
increases expression decreases expression multiple interactions
EXP ISO
bexarotene results in increased expression of CCND1 mRNA bexarotene results in decreased expression of CCND1 mRNA [Raloxifene Hydrochloride co-treated with Bexarotene] affects the reaction [Azoxymethane affects the expression of CCND1 mRNA]; [Raloxifene Hydrochloride co-treated with Bexarotene] affects the reaction [Azoxymethane affects the expression of CCND1 protein]; Bexarotene affects the reaction [Azoxymethane affects the expression of CCND1 mRNA]; Bexarotene affects the reaction [Azoxymethane affects the expression of CCND1 protein]
CTD
PMID:16648578 PMID:17178900 PMID:24080207
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
G
Ccne1
cyclin E1
decreases expression
ISO
bexarotene results in decreased expression of CCNE1 mRNA
CTD
PMID:17849452
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
G
Cd14
CD14 molecule
increases expression
EXP
bexarotene results in increased expression of CD14 mRNA
CTD
PMID:16648578
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
G
Cd36
CD36 molecule
increases expression
EXP
bexarotene results in increased expression of CD36 mRNA
CTD
PMID:16648578 PMID:23292798
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
G
Cd37
CD37 molecule
increases expression
EXP
bexarotene results in increased expression of CD37 mRNA
CTD
PMID:16648578
NCBI chr 1:95,719,171...95,724,662
Ensembl chr 1:95,719,190...95,724,648
G
Cd48
Cd48 molecule
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of CD48 mRNA
CTD
PMID:17630414
NCBI chr13:84,184,884...84,209,144
Ensembl chr13:84,185,532...84,209,142
G
Cd5l
Cd5 molecule-like
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of CD5L mRNA
CTD
PMID:17630414
NCBI chr 2:172,791,007...172,802,018
Ensembl chr 2:172,790,934...172,829,753
G
Cd68
Cd68 molecule
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of CD68 mRNA
CTD
PMID:17630414
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
G
Cd74
CD74 molecule
increases expression
EXP
bexarotene results in increased expression of CD74 mRNA
CTD
PMID:16648578
NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
G
Cdc37
cell division cycle 37, HSP90 cochaperone
increases expression
EXP
bexarotene results in increased expression of CDC37 mRNA
CTD
PMID:16648578
NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809
G
Cdk1
cyclin-dependent kinase 1
decreases expression
ISO
bexarotene results in decreased expression of CDK1 protein
CTD
PMID:19067706
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
G
Cdk2
cyclin dependent kinase 2
multiple interactions
EXP
[Raloxifene Hydrochloride co-treated with Bexarotene] affects the reaction [Azoxymethane affects the expression of CDK2 protein]
CTD
PMID:24080207
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
G
Cdkn1a
cyclin-dependent kinase inhibitor 1A
increases expression multiple interactions
ISO EXP
bexarotene results in increased expression of CDKN1A protein [Raloxifene Hydrochloride co-treated with Bexarotene] affects the reaction [Azoxymethane affects the expression of CDKN1A protein]; Bexarotene affects the reaction [Azoxymethane affects the expression of CDKN1A protein]
CTD
PMID:19067706 PMID:24080207
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
G
Cdo1
cysteine dioxygenase type 1
decreases expression
EXP
bexarotene results in decreased expression of CDO1 mRNA
CTD
PMID:16648578
NCBI chr18:39,432,473...39,447,253
Ensembl chr18:39,432,474...39,447,296
G
Cebpg
CCAAT/enhancer binding protein gamma
decreases expression
ISO
bexarotene results in decreased expression of CEBPG mRNA
CTD
PMID:17178900
NCBI chr 1:87,683,060...87,692,772
Ensembl chr 1:87,684,019...87,694,569
G
Ces2h
carboxylesterase 2H
increases expression multiple interactions
EXP
bexarotene results in increased expression of CES2 mRNA [Tamoxifen co-treated with bexarotene] results in increased expression of CES2 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
G
Cfd
complement factor D
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of CFD mRNA
CTD
PMID:17630414
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
G
Chrna2
cholinergic receptor nicotinic alpha 2 subunit
increases expression
EXP
bexarotene results in increased expression of CHRNA2 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601
G
Ciao1
cytosolic iron-sulfur assembly component 1
decreases expression
EXP
bexarotene results in decreased expression of CIAO1 mRNA
CTD
PMID:16648578
NCBI chr 3:114,458,671...114,465,928
Ensembl chr 3:114,458,655...114,467,009
G
Cimap1b
ciliary microtubule associated protein 1B
multiple interactions
EXP
[Bexarotene co-treated with Tamoxifen] results in increased expression of CIMAP1B mRNA
CTD
PMID:17630414
NCBI chr 7:120,444,232...120,447,294
Ensembl chr 7:120,444,232...120,446,749
G
Ckb
creatine kinase B
increases expression
EXP
bexarotene results in increased expression of CKB mRNA
CTD
PMID:16648578
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
G
Cldn3
claudin 3
increases expression
EXP
bexarotene results in increased expression of CLDN3 mRNA
CTD
PMID:16648578
NCBI chr12:21,708,538...21,710,010
Ensembl chr12:21,708,398...21,711,001
G
Cldn7
claudin 7
increases expression
EXP
bexarotene results in increased expression of CLDN7 mRNA
CTD
PMID:16648578
NCBI chr10:54,689,684...54,692,177
Ensembl chr10:54,689,987...54,692,171
G
Col12a1
collagen type XII alpha 1 chain
decreases expression
EXP
bexarotene results in decreased expression of COL12A1 mRNA
CTD
PMID:16648578
NCBI chr 8:80,547,592...80,665,665
Ensembl chr 8:80,547,593...80,665,686
G
Colq
collagen like tail subunit of asymmetric acetylcholinesterase
increases expression
EXP
bexarotene results in increased expression of COLQ mRNA
CTD
PMID:16648578
NCBI chr16:6,731,850...6,824,973
Ensembl chr16:6,731,858...6,787,107
G
Comt
catechol-O-methyltransferase
decreases expression increases expression
EXP
bexarotene results in decreased expression of COMT mRNA bexarotene results in increased expression of COMT mRNA
CTD
PMID:16648578
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
G
Coro1b
coronin 1B
increases expression
EXP
bexarotene results in increased expression of CORO1B mRNA
CTD
PMID:16648578
NCBI chr 1:201,442,977...201,448,416
Ensembl chr 1:201,443,014...201,448,416
G
Cpa1
carboxypeptidase A1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of CPA1 mRNA
CTD
PMID:17630414
NCBI chr 4:59,257,417...59,263,544
Ensembl chr 4:59,257,417...59,263,544
G
Cps1
carbamoyl-phosphate synthase 1
decreases expression
EXP
bexarotene results in decreased expression of CPS1 mRNA
CTD
PMID:16648578
NCBI chr 9:68,614,153...68,737,037
Ensembl chr 9:68,614,153...68,737,033
G
Cpt1b
carnitine palmitoyltransferase 1B
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of CPT1B mRNA
CTD
PMID:17630414
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
G
Cpt2
carnitine palmitoyltransferase 2
increases expression
EXP
bexarotene results in increased expression of CPT2 mRNA
CTD
PMID:16648578
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
G
Crot
carnitine O-octanoyltransferase
increases expression
EXP
bexarotene results in increased expression of CROT mRNA
CTD
PMID:16648578
NCBI chr 4:25,068,270...25,133,111
Ensembl chr 4:25,080,587...25,133,109
G
Csf1r
colony stimulating factor 1 receptor
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of CSF1R mRNA
CTD
PMID:17630414
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
G
Cspg5
chondroitin sulfate proteoglycan 5
increases expression
EXP
bexarotene results in increased expression of CSPG5 mRNA
CTD
PMID:16648578
NCBI chr 8:110,220,506...110,234,766
Ensembl chr 8:110,220,653...110,234,758
G
Csrp2
cysteine and glycine-rich protein 2
decreases expression
EXP
bexarotene results in decreased expression of CSRP2 mRNA
CTD
PMID:16648578
NCBI chr 7:46,349,109...46,367,743
Ensembl chr 7:46,348,686...46,367,745
G
Cth
cystathionine gamma-lyase
decreases expression
ISO
bexarotene results in decreased expression of CTH mRNA
CTD
PMID:17178900
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
G
Ctnnb1
catenin beta 1
multiple interactions
EXP
[Raloxifene Hydrochloride co-treated with Bexarotene] affects the reaction [Azoxymethane affects the expression of CTNNB1 mRNA]; [Raloxifene Hydrochloride co-treated with Bexarotene] affects the reaction [Azoxymethane affects the expression of CTNNB1 protein]; Bexarotene affects the reaction [Azoxymethane affects the expression of CTNNB1 mRNA]; Bexarotene affects the reaction [Azoxymethane affects the expression of CTNNB1 protein]
CTD
PMID:24080207
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
G
Ctrc
chymotrypsin C
increases expression
EXP
bexarotene results in increased expression of CTRC mRNA
CTD
PMID:16648578
NCBI chr 5:154,147,314...154,156,540
Ensembl chr 5:154,147,316...154,156,528
G
Ctsh
cathepsin H
increases expression
ISO
bexarotene results in increased expression of CTSH mRNA
CTD
PMID:17178900
NCBI chr 8:90,608,941...90,627,824
Ensembl chr 8:90,608,941...90,627,824
G
Cxcl1
C-X-C motif chemokine ligand 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of CXCL1 mRNA
CTD
PMID:17630414
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
G
Cxcl14
C-X-C motif chemokine ligand 14
decreases expression
EXP
bexarotene results in decreased expression of CXCL14 mRNA
CTD
PMID:16648578
NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839
G
Cxcl3
C-X-C motif chemokine ligand 3
decreases expression
EXP
bexarotene results in decreased expression of CXCL3 mRNA
CTD
PMID:16648578
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
G
Cyb5a
cytochrome b5 type A
decreases expression
EXP
bexarotene results in decreased expression of CYB5A mRNA
CTD
PMID:16648578
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
G
Cycs
cytochrome c, somatic
decreases expression
ISO
bexarotene results in decreased expression of CYCS mRNA
CTD
PMID:17178900
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
G
Cyp17a1
cytochrome P450, family 17, subfamily a, polypeptide 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of CYP17A1 mRNA
CTD
PMID:17630414
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
G
Cyp1a2
cytochrome P450, family 1, subfamily a, polypeptide 2
decreases expression
EXP
bexarotene results in decreased expression of CYP1A2 mRNA
CTD
PMID:16648578
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
G
Cyp1b1
cytochrome P450, family 1, subfamily b, polypeptide 1
increases expression
EXP
bexarotene results in increased expression of CYP1B1 mRNA
CTD
PMID:16648578
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
G
Cyp26a1
cytochrome P450, family 26, subfamily a, polypeptide 1
increases expression multiple interactions
ISO EXP
bexarotene results in increased expression of CYP26A1 mRNA [bexarotene co-treated with Tamoxifen] results in increased expression of CYP26A1 mRNA
CTD
PMID:17178900 PMID:17630414
NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204
G
Cyp26b1
cytochrome P450, family 26, subfamily b, polypeptide 1
increases expression
ISO
bexarotene results in increased expression of CYP26B1 mRNA
CTD
PMID:17849452
NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
G
Cyp27a1
cytochrome P450, family 27, subfamily a, polypeptide 1
increases expression
EXP
bexarotene results in increased expression of CYP27A1 mRNA
CTD
PMID:16648578
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
G
Cyp2a1
cytochrome P450, family 2, subfamily a, polypeptide 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of CYP2A1 mRNA
CTD
PMID:17630414
NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887
G
Cyp2a2
cytochrome P450, family 2, subfamily a, polypeptide 2
decreases expression
EXP
bexarotene results in decreased expression of CYP2A2 mRNA
CTD
PMID:16648578
NCBI chr 1:82,263,833...82,289,487
Ensembl chr 1:82,263,833...82,289,487
G
Cyp2b1
cytochrome P450, family 2, subfamily b, polypeptide 1
increases expression
EXP
bexarotene results in increased expression of CYP2B1 mRNA
CTD
PMID:23292798
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
G
Cyp2b15
cytochrome P450, family 2, subfamily b, polypeptide 15
increases expression
EXP
bexarotene results in increased expression of CYP2B15 mRNA
CTD
PMID:16648578
NCBI chr 1:82,094,188...82,106,492
Ensembl chr 1:82,094,180...82,106,492
G
Cyp2b2
cytochrome P450, family 2, subfamily b, polypeptide 2
increases expression
EXP
bexarotene results in increased expression of CYP2B2 mRNA
CTD
PMID:16648578
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
G
Cyp2b3
cytochrome P450, family 2, subfamily b, polypeptide 3
increases expression multiple interactions
ISO
Bexarotene results in increased expression of CYP2B6 mRNA RXRA protein affects the reaction [Bexarotene results in increased expression of CYP2B6 mRNA]
CTD
PMID:31312845
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
G
Cyp2c12
cytochrome P450, family 2, subfamily c, polypeptide 12
decreases expression
EXP
bexarotene results in decreased expression of CYP2C12 mRNA
CTD
PMID:16648578
NCBI chr 1:238,699,859...238,757,011
Ensembl chr 1:238,699,854...238,757,019
G
Cyp2c7
cytochrome P450, family 2, subfamily c, polypeptide 7
decreases expression
EXP
bexarotene results in decreased expression of CYP2C7 mRNA
CTD
PMID:16648578
NCBI chr 1:237,332,641...237,388,714
Ensembl chr 1:237,332,659...237,388,709
G
Cyp2d3
cytochrome P450, family 2, subfamily d, polypeptide 3
increases expression
EXP
bexarotene results in increased expression of CYP2D3 mRNA
CTD
PMID:16648578
NCBI chr 7:113,917,711...113,922,068
Ensembl chr 7:113,908,947...113,922,084
G
Cyp2t1
cytochrome P450, family 2, subfamily t, polypeptide 1
decreases expression multiple interactions
EXP
bexarotene results in decreased expression of CYP2T1 mRNA [Tamoxifen co-treated with bexarotene] results in decreased expression of CYP2T1 mRNA
CTD
PMID:17630414
NCBI chr 1:82,446,321...82,451,564
Ensembl chr 1:82,446,921...82,451,563
G
Cyp3a18
cytochrome P450, family 3, subfamily a, polypeptide 18
decreases expression
EXP
bexarotene results in decreased expression of CYP3A18 mRNA
CTD
PMID:16648578
NCBI chr12:8,880,509...8,930,382
Ensembl chr12:8,880,528...8,930,381
G
Cyp3a23-3a1
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1
decreases expression increases expression
EXP
Bexarotene results in decreased expression of CYP3A23-3A1 mRNA Bexarotene results in increased expression of CYP3A23-3A1 mRNA
CTD
PMID:16648578 PMID:23292798
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
G
Cyp4a1
cytochrome P450, family 4, subfamily a, polypeptide 1
increases expression
EXP
bexarotene results in increased expression of CYP4A22 mRNA
CTD
PMID:16648578
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
G
Cyp4f1
cytochrome P450, family 4, subfamily f, polypeptide 1
decreases expression
EXP
bexarotene results in decreased expression of CYP4F1 mRNA
CTD
PMID:16648578
NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,010,852...12,022,046
G
Cyp8b1
cytochrome P450 family 8 subfamily B member 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of CYP8B1 mRNA
CTD
PMID:17630414
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
G
Dab2
DAB adaptor protein 2
decreases expression
EXP
Bexarotene results in decreased expression of DAB2 mRNA
CTD
PMID:16648578
NCBI chr 2:55,514,692...55,567,476
Ensembl chr 2:55,514,700...55,567,476
G
Dact2
dishevelled-binding antagonist of beta-catenin 2
increases expression
EXP
bexarotene results in increased expression of DACT2 mRNA
CTD
PMID:17630414
NCBI chr 1:55,181,023...55,191,026
Ensembl chr 1:55,181,024...55,191,096
G
Dapk3
death-associated protein kinase 3
decreases expression
EXP
bexarotene results in decreased expression of DAPK3 mRNA
CTD
PMID:16648578
NCBI chr 7:8,524,182...8,532,552
Ensembl chr 7:8,524,183...8,532,558
G
Dbp
D-box binding PAR bZIP transcription factor
decreases expression
EXP
bexarotene results in decreased expression of DBP mRNA
CTD
PMID:16648578
NCBI chr 1:96,175,796...96,180,745
Ensembl chr 1:96,175,440...96,180,745
G
Ddit3
DNA-damage inducible transcript 3
decreases expression
EXP
bexarotene results in decreased expression of DDIT3 mRNA
CTD
PMID:16648578
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
G
Ddit4
DNA-damage-inducible transcript 4
increases expression
ISO
bexarotene results in increased expression of DDIT4 mRNA
CTD
PMID:17178900
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
G
Decr2
2,4-dienoyl-CoA reductase 2
increases expression
EXP
bexarotene results in increased expression of DECR2 mRNA
CTD
PMID:16648578
NCBI chr10:15,104,907...15,113,281
Ensembl chr10:15,002,926...15,118,479
G
Depp1
DEPP autophagy regulator 1
increases expression
ISO
bexarotene results in increased expression of DEPP1 mRNA
CTD
PMID:17178900
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
G
Dhcr7
7-dehydrocholesterol reductase
increases expression
EXP
bexarotene results in increased expression of DHCR7 mRNA
CTD
PMID:16648578
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
G
Dhrs3
dehydrogenase/reductase 3
increases expression
ISO
bexarotene results in increased expression of DHRS3 mRNA
CTD
PMID:17178900
NCBI chr 5:156,747,939...156,782,420
Ensembl chr 5:156,747,962...156,782,417
G
Dkk1
dickkopf WNT signaling pathway inhibitor 1
increases expression
ISO
bexarotene results in increased expression of DKK1 mRNA
CTD
PMID:17178900
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
G
Dlat
dihydrolipoamide S-acetyltransferase
increases expression
EXP
bexarotene results in increased expression of DLAT mRNA
CTD
PMID:16648578
NCBI chr 8:50,979,151...51,004,435
Ensembl chr 8:50,978,051...51,004,479
G
Dmp1
dentin matrix acidic phosphoprotein 1
multiple interactions
ISO
bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]
CTD
PMID:25932594
NCBI chr14:5,528,441...5,542,078
Ensembl chr14:5,528,431...5,539,323
G
Dnaja1
DnaJ heat shock protein family (Hsp40) member A1
decreases expression
EXP
bexarotene results in decreased expression of DNAJA1 mRNA
CTD
PMID:16648578
NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967
G
Dnmt3a
DNA methyltransferase 3 alpha
decreases expression
ISO
bexarotene results in decreased expression of DNMT3A mRNA
CTD
PMID:17849452
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
G
Dusp1
dual specificity phosphatase 1
decreases expression
ISO EXP
bexarotene results in decreased expression of DUSP1 mRNA
CTD
PMID:16648578 PMID:17178900
NCBI chr10:16,680,478...16,683,275
G
Dusp5
dual specificity phosphatase 5
decreases expression
ISO
bexarotene results in decreased expression of DUSP5 mRNA
CTD
PMID:17178900
NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
G
Dync1i2
dynein cytoplasmic 1 intermediate chain 2
decreases expression
EXP
bexarotene results in decreased expression of DYNC1I2 mRNA
CTD
PMID:16648578
NCBI chr 3:56,033,882...56,085,080
Ensembl chr 3:56,033,917...56,085,080
G
Ech1
enoyl-CoA hydratase 1
increases expression
EXP
bexarotene results in increased expression of ECH1 mRNA
CTD
PMID:23292798
NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795
G
Echdc1
ethylmalonyl-CoA decarboxylase 1
increases expression
EXP
bexarotene results in increased expression of ECHDC1 mRNA
CTD
PMID:23292798
NCBI chr 1:28,476,354...28,507,173
Ensembl chr 1:28,476,200...28,507,319
G
Eci1
enoyl-CoA delta isomerase 1
increases expression
EXP
bexarotene results in increased expression of ECI1 mRNA
CTD
PMID:16648578
NCBI chr10:13,456,715...13,470,061
Ensembl chr10:13,456,563...13,470,061
G
Ednrb
endothelin receptor type B
increases expression
EXP
bexarotene results in increased expression of EDNRB mRNA
CTD
PMID:16648578
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
G
Egf
epidermal growth factor
increases expression
EXP
bexarotene results in increased expression of EGF mRNA
CTD
PMID:16648578
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
G
Egr1
early growth response 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of EGR1 mRNA
CTD
PMID:17630414
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
G
Egr3
early growth response 3
decreases expression
ISO
bexarotene results in decreased expression of EGR3 mRNA
CTD
PMID:17178900
NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627
G
Ehhadh
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase
multiple interactions increases expression
EXP
[Tamoxifen co-treated with bexarotene] results in increased expression of EHHADH mRNA bexarotene results in increased expression of EHHADH mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188
G
Eif1
eukaryotic translation initiation factor 1
decreases expression
ISO
bexarotene results in decreased expression of EIF1 mRNA
CTD
PMID:17178900
NCBI chr10:85,246,751...85,248,842
Ensembl chr10:85,246,764...85,427,327
G
Eif3c
eukaryotic translation initiation factor 3, subunit C
decreases expression
EXP
bexarotene results in decreased expression of EIF3C mRNA
CTD
PMID:17630414
NCBI chr 1:181,134,604...181,152,489
Ensembl chr 1:181,134,604...181,152,493
G
Elovl6
ELOVL fatty acid elongase 6
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of ELOVL6 mRNA
CTD
PMID:17630414
NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186
G
Eno1
enolase 1
increases expression
EXP
bexarotene results in increased expression of ENO1 mRNA
CTD
PMID:16648578
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
G
Enpp2
ectonucleotide pyrophosphatase/phosphodiesterase 2
decreases expression
EXP
bexarotene results in decreased expression of ENPP2 mRNA
CTD
PMID:16648578
NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827
G
Epha2
Eph receptor A2
decreases expression
ISO
bexarotene results in decreased expression of EPHA2 mRNA
CTD
PMID:17178900
NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117
G
Ephx1
epoxide hydrolase 1
increases expression
EXP
bexarotene results in increased expression of EPHX1 mRNA
CTD
PMID:23292798
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
G
Ephx2
epoxide hydrolase 2
increases expression
EXP
bexarotene results in increased expression of EPHX2 mRNA
CTD
PMID:23292798
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
G
Erp29
endoplasmic reticulum protein 29
increases expression
EXP
bexarotene results in increased expression of ERP29 mRNA
CTD
PMID:16648578
NCBI chr12:35,089,698...35,095,952
Ensembl chr12:35,089,707...35,096,376
G
Esr1
estrogen receptor 1
decreases expression
ISO
bexarotene results in decreased expression of ESR1 mRNA
CTD
PMID:17849452
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
G
Esr2
estrogen receptor 2
multiple interactions
ISO EXP
bexarotene binds to and results in decreased activity of ESR2 protein [Raloxifene Hydrochloride co-treated with Bexarotene] affects the reaction [Azoxymethane affects the expression of ESR2 mRNA]; [Raloxifene Hydrochloride co-treated with Bexarotene] affects the reaction [Azoxymethane affects the expression of ESR2 protein]; Bexarotene affects the reaction [Azoxymethane affects the expression of ESR2 mRNA]; Bexarotene affects the reaction [Azoxymethane affects the expression of ESR2 protein]
CTD
PMID:24080207 PMID:25752796
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
G
F2
coagulation factor II, thrombin
decreases expression
EXP
bexarotene results in decreased expression of F2 mRNA
CTD
PMID:16648578
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
G
Fabp1
fatty acid binding protein 1
decreases expression
EXP
bexarotene results in decreased expression of FABP1 mRNA
CTD
PMID:16648578
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
G
Fabp2
fatty acid binding protein 2
decreases expression multiple interactions
EXP
bexarotene results in decreased expression of FABP2 mRNA [Tamoxifen co-treated with bexarotene] results in decreased expression of FABP2 mRNA
CTD
PMID:17630414
NCBI chr 2:211,040,032...211,044,089
Ensembl chr 2:211,040,032...211,044,089
G
Fabp3
fatty acid binding protein 3
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of FABP3 mRNA
CTD
PMID:17630414
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
G
Fabp4
fatty acid binding protein 4
increases expression
ISO
bexarotene results in increased expression of FABP4 mRNA; bexarotene results in increased expression of FABP4 protein
CTD
PMID:21622945 PMID:25932594
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
G
Fads2
fatty acid desaturase 2
increases expression multiple interactions
EXP
bexarotene results in increased expression of FADS2 mRNA [Tamoxifen co-treated with bexarotene] results in increased expression of FADS2 mRNA
CTD
PMID:17630414
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
G
Fam13a
family with sequence similarity 13, member A
decreases expression
EXP
bexarotene results in decreased expression of FAM13A mRNA
CTD
PMID:17630414
NCBI chr 4:88,056,521...88,155,782
Ensembl chr 4:88,058,403...88,155,860
G
Fasn
fatty acid synthase
multiple interactions increases expression
EXP ISO
[Tamoxifen co-treated with bexarotene] results in increased expression of FASN mRNA bexarotene results in increased expression of FASN mRNA [Bexarotene co-treated with GW 3965] results in increased expression of FASN mRNA; [Bexarotene co-treated with paxilline] results in increased expression of FASN mRNA; [Bexarotene co-treated with T0901317] results in increased expression of FASN mRNA
CTD
PMID:16648578 PMID:17630414 PMID:32123961
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
G
Fcgr2a
Fc gamma receptor 2A
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of FCGR3 mRNA
CTD
PMID:17630414
NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967
G
Fcgr2b
Fc gamma receptor 2B
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of FCGR2B mRNA
CTD
PMID:17630414
NCBI chr13:83,191,253...83,207,778
Ensembl chr13:83,193,163...83,207,778
G
Fdft1
farnesyl diphosphate farnesyl transferase 1
increases expression
EXP
bexarotene results in increased expression of FDFT1 mRNA
CTD
PMID:16648578
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
G
Fga
fibrinogen alpha chain
decreases expression
EXP
bexarotene results in decreased expression of FGA mRNA
CTD
PMID:16648578
NCBI chr 2:168,374,120...168,381,523
Ensembl chr 2:168,374,120...168,381,528
G
Fgb
fibrinogen beta chain
decreases expression
EXP
bexarotene results in decreased expression of FGB mRNA
CTD
PMID:16648578
NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
G
Fgg
fibrinogen gamma chain
decreases expression
EXP
bexarotene results in decreased expression of FGG mRNA
CTD
PMID:16648578
NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322
G
Fh
fumarate hydratase
decreases expression
EXP
bexarotene results in decreased expression of FH1 mRNA
CTD
PMID:16648578
NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266
G
Fmo1
flavin containing dimethylaniline monoxygenase 1
decreases expression
EXP
bexarotene results in decreased expression of FMO1 mRNA
CTD
PMID:16648578
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
G
Fn1
fibronectin 1
increases expression
EXP
bexarotene results in increased expression of FN1 mRNA
CTD
PMID:16648578
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
G
Foxa1
forkhead box A1
increases expression
EXP
bexarotene results in increased expression of FOXA1 mRNA
CTD
PMID:16648578
NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188
G
Foxa2
forkhead box A2
decreases expression
EXP
bexarotene results in decreased expression of FOXA2 mRNA
CTD
PMID:16648578
NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:135,470,131...135,474,326
G
Galr2
galanin receptor 2
increases expression
EXP
bexarotene results in increased expression of GALR2 mRNA
CTD
PMID:16648578
NCBI chr10:101,513,689...101,517,176
Ensembl chr10:101,514,471...101,517,176
G
Gars1
glycyl-tRNA synthetase 1
decreases expression
ISO
Bexarotene results in decreased expression of GARS1 mRNA
CTD
PMID:17178900
NCBI chr 4:84,171,596...84,212,609
Ensembl chr 4:84,171,596...84,212,609
G
Gas6
growth arrest specific 6
decreases expression multiple interactions
EXP
bexarotene results in decreased expression of GAS6 mRNA [bexarotene co-treated with Tamoxifen] results in decreased expression of GAS6 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904
G
Gas7
growth arrest specific 7
increases expression
EXP
bexarotene results in increased expression of GAS7 mRNA
CTD
PMID:16648578
NCBI chr10:52,152,718...52,383,283
Ensembl chr10:52,152,493...52,383,276
G
Gc
GC, vitamin D binding protein
decreases expression
EXP
bexarotene results in decreased expression of GC mRNA
CTD
PMID:16648578
NCBI chr14:18,632,146...18,667,563
Ensembl chr14:18,632,135...18,667,567
G
Gcgr
glucagon receptor
decreases expression
EXP
bexarotene results in decreased expression of GCGR mRNA
CTD
PMID:16648578
NCBI chr10:105,808,474...105,816,641
Ensembl chr10:105,808,473...105,816,640
G
Ghrh
growth hormone releasing hormone
increases expression
EXP
bexarotene results in increased expression of GHRH mRNA
CTD
PMID:16648578
NCBI chr 3:145,992,762...146,012,528
Ensembl chr 3:145,992,763...146,011,889
G
Glra3
glycine receptor, alpha 3
increases expression
EXP
bexarotene results in increased expression of GLRA3 mRNA
CTD
PMID:16648578
NCBI chr16:34,199,937...34,848,773
Ensembl chr16:34,204,811...34,848,753
G
Gosr1
golgi SNAP receptor complex member 1
increases expression
EXP
bexarotene results in increased expression of GOSR1 mRNA
CTD
PMID:16648578
NCBI chr10:61,570,499...61,607,287
Ensembl chr10:61,450,494...61,607,177 Ensembl chr10:61,450,494...61,607,177
G
Gpd1
glycerol-3-phosphate dehydrogenase 1
increases expression
EXP
bexarotene results in increased expression of GPD1 mRNA
CTD
PMID:23292798
NCBI chr 7:130,842,526...130,851,530
Ensembl chr 7:130,844,138...130,851,529
G
Gpd2
glycerol-3-phosphate dehydrogenase 2
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of GPD2 mRNA
CTD
PMID:17630414
NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901
G
Gpm6a
glycoprotein m6a
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of GPM6A mRNA
CTD
PMID:17630414
NCBI chr16:36,641,282...36,973,377
Ensembl chr16:36,641,284...36,973,475
G
Gpm6b
glycoprotein m6b
increases expression
ISO
bexarotene results in increased expression of GPM6B mRNA
CTD
PMID:17178900
NCBI chr X:28,057,788...28,204,409
Ensembl chr X:28,059,450...28,204,211
G
Gpx4
glutathione peroxidase 4
increases expression
EXP
bexarotene results in increased expression of GPX4 mRNA
CTD
PMID:16648578
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
G
Grin2c
glutamate ionotropic receptor NMDA type subunit 2C
increases expression
EXP
bexarotene results in increased expression of GRIN2C mRNA
CTD
PMID:17630414
NCBI chr10:100,488,430...100,507,083
Ensembl chr10:100,488,431...100,506,427
G
Grina
glutamate ionotropic receptor NMDA type subunit associated protein 1
increases expression
EXP
bexarotene results in increased expression of GRINA mRNA
CTD
PMID:16648578
NCBI chr 7:107,962,194...107,965,372
Ensembl chr 7:107,962,207...107,965,366
G
Grk2
G protein-coupled receptor kinase 2
increases expression
EXP
bexarotene results in increased expression of GRK2 mRNA
CTD
PMID:16648578
NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582
G
Gsta5
glutathione S-transferase alpha 5
increases expression
EXP
bexarotene results in increased expression of GSTA5 mRNA
CTD
PMID:23292798
NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472
G
Gstm5l
glutathione S-transferase, mu 5-like
increases expression
EXP
Bexarotene results in increased expression of GSTM5 mRNA
CTD
PMID:17630414
NCBI chr 2:195,544,424...195,549,895
Ensembl chr 2:195,544,426...195,628,961
G
Gys2
glycogen synthase 2
decreases expression increases expression
EXP
bexarotene results in decreased expression of GYS2 mRNA bexarotene results in increased expression of GYS2 mRNA
CTD
PMID:16648578 PMID:23292798
NCBI chr 4:175,365,054...175,406,228
Ensembl chr 4:175,365,054...175,406,228
G
H2az1
H2A.Z variant histone 1
decreases expression
EXP
Bexarotene results in decreased expression of H2AZ1 mRNA
CTD
PMID:16648578
NCBI chr 2:226,355,668...226,357,984
Ensembl chr 2:226,355,708...226,358,485
G
Hao2
hydroxyacid oxidase 2
decreases expression
EXP
bexarotene results in decreased expression of HAO2 mRNA
CTD
PMID:17630414
NCBI chr 2:186,200,137...186,232,997
Ensembl chr 2:186,200,504...186,224,425
G
Herpud1
homocysteine inducible ER protein with ubiquitin like domain 1
decreases expression
ISO
bexarotene results in decreased expression of HERPUD1 mRNA
CTD
PMID:17178900
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
G
Hmgb2
high mobility group box 2
decreases expression
EXP
bexarotene results in decreased expression of HMGB2 mRNA
CTD
PMID:16648578
NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140
G
Homer1
homer scaffold protein 1
increases expression
EXP
bexarotene results in increased expression of HOMER1 mRNA
CTD
PMID:16648578
NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785
G
Hp
haptoglobin
decreases expression
EXP
bexarotene results in decreased expression of HP mRNA
CTD
PMID:16648578
NCBI chr19:37,539,626...37,544,178
Ensembl chr19:37,539,627...37,544,523
G
Hpgds
hematopoietic prostaglandin D synthase
increases expression
EXP
bexarotene results in increased expression of HPGDS mRNA
CTD
PMID:16648578
NCBI chr 4:94,368,426...94,397,931
Ensembl chr 4:94,373,342...94,397,883
G
Hsd11b2
hydroxysteroid 11-beta dehydrogenase 2
increases expression multiple interactions
ISO
Bexarotene results in increased expression of HSD11B2 mRNA Bexarotene results in increased expression of and results in increased activity of HSD11B2 protein; Cycloheximide promotes the reaction [Bexarotene results in increased expression of HSD11B2 mRNA]; Dactinomycin inhibits the reaction [Bexarotene results in increased expression of HSD11B2 mRNA]; LG 100754 inhibits the reaction [Bexarotene results in increased activity of HSD11B2 protein]; RXRA protein affects the reaction [Bexarotene results in increased expression of HSD11B2 mRNA]; RXRA protein affects the reaction [Bexarotene results in increased expression of HSD11B2 protein]
CTD
PMID:31927052
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
G
Hsd17b12
hydroxysteroid (17-beta) dehydrogenase 12
increases expression
EXP
bexarotene results in increased expression of HSD17B12 mRNA
CTD
PMID:16648578
NCBI chr 3:79,990,048...80,113,556
Ensembl chr 3:79,990,056...80,113,617
G
Hsd17b2
hydroxysteroid (17-beta) dehydrogenase 2
decreases expression
EXP
bexarotene results in decreased expression of HSD17B2 mRNA
CTD
PMID:16648578
NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202
G
Hspa4
heat shock protein family A (Hsp70) member 4
decreases expression
EXP
bexarotene results in decreased expression of HSPA4 mRNA
CTD
PMID:16648578
NCBI chr10:37,408,025...37,449,080
Ensembl chr10:37,408,025...37,449,001
G
Hspa9
heat shock protein family A (Hsp70) member 9
increases expression
EXP
bexarotene results in increased expression of HSPA9 mRNA
CTD
PMID:16648578
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
G
Hspb1
heat shock protein family B (small) member 1
increases expression
EXP
bexarotene results in increased expression of HSPB1 mRNA
CTD
PMID:16648578
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
G
Hsph1
heat shock protein family H (Hsp110) member 1
decreases expression
EXP
bexarotene results in decreased expression of HSPH1 mRNA
CTD
PMID:16648578
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
G
Id1
inhibitor of DNA binding 1
increases expression
ISO
bexarotene results in increased expression of ID1 mRNA; bexarotene results in increased expression of ID1 protein
CTD
PMID:17178900
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
G
Ier2
immediate early response 2
decreases expression
ISO
bexarotene results in decreased expression of IER2 mRNA
CTD
PMID:17178900
NCBI chr19:23,494,551...23,496,075
Ensembl chr19:23,494,184...23,499,211
G
Ifitm1
interferon induced transmembrane protein 1
multiple interactions
EXP
[Bexarotene co-treated with Tamoxifen] results in decreased expression of IFITM1 mRNA
CTD
PMID:17630414
NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169
G
Ifngr1
interferon gamma receptor 1
increases expression
EXP
bexarotene results in increased expression of IFNGR1 mRNA
CTD
PMID:16648578
NCBI chr 1:14,333,167...14,351,799
Ensembl chr 1:14,333,187...14,351,785
G
Igf1
insulin-like growth factor 1
decreases expression
EXP
bexarotene results in decreased expression of IGF1 protein
CTD
PMID:15591091
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
G
Igf2
insulin-like growth factor 2
increases expression
EXP
bexarotene results in increased expression of IGF2 mRNA
CTD
PMID:16648578
NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
G
Igfbp1
insulin-like growth factor binding protein 1
increases expression
EXP
bexarotene results in increased expression of IGFBP1 mRNA
CTD
PMID:16648578
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
G
Igfbp2
insulin-like growth factor binding protein 2
increases expression multiple interactions
EXP
bexarotene results in increased expression of IGFBP2 mRNA [Tamoxifen co-treated with bexarotene] results in increased expression of IGFBP2 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
G
Igfbp3
insulin-like growth factor binding protein 3
multiple interactions decreases expression
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of IGFBP3 mRNA bexarotene results in decreased expression of IGFBP3 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
G
Igfbp6
insulin-like growth factor binding protein 6
increases expression
ISO
bexarotene results in increased expression of IGFBP6 mRNA; bexarotene results in increased expression of IGFBP6 protein
CTD
PMID:17178900
NCBI chr 7:133,276,309...133,280,944
Ensembl chr 7:133,276,234...133,280,966
G
Igfbp7
insulin-like growth factor binding protein 7
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of IGFBP7 mRNA
CTD
PMID:17630414
NCBI chr14:30,737,414...30,797,317
Ensembl chr14:30,737,164...30,797,314
G
Il15
interleukin 15
increases expression
ISO
bexarotene results in increased expression of IL15 mRNA
CTD
PMID:17178900
NCBI chr19:25,640,025...25,706,818
Ensembl chr19:25,640,251...25,706,820
G
Il18
interleukin 18
decreases expression
EXP
bexarotene results in decreased expression of IL18 mRNA
CTD
PMID:16648578
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
G
Il4
interleukin 4
decreases expression multiple interactions
ISO EXP
bexarotene results in decreased expression of IL4 protein [Raloxifene Hydrochloride co-treated with Bexarotene] affects the reaction [Azoxymethane affects the expression of IL4 mRNA]; Bexarotene affects the reaction [Azoxymethane affects the expression of IL4 mRNA]
CTD
PMID:15781672 PMID:24080207
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
G
Il6r
interleukin 6 receptor
decreases expression
EXP
bexarotene results in decreased expression of IL6RA mRNA
CTD
PMID:16648578
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
G
Ins2
insulin 2
multiple interactions
ISO
[bexarotene co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA] [[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] co-treated with bexarotene] results in increased expression of SLC27A1 mRNA; [Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] results in increased susceptibility to bexarotene
CTD
PMID:10777552 PMID:25932594
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
G
Insig1
insulin induced gene 1
increases expression
EXP
bexarotene results in increased expression of INSIG1 mRNA
CTD
PMID:16648578
NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952
G
Insrr
insulin receptor-related receptor
increases expression
EXP
bexarotene results in increased expression of INSRR mRNA
CTD
PMID:16648578
NCBI chr 2:173,255,335...173,274,800
Ensembl chr 2:173,255,414...173,274,800
G
Irf1
interferon regulatory factor 1
increases expression
EXP
bexarotene results in increased expression of IRF1 mRNA
CTD
PMID:16648578
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
G
Itga7
integrin subunit alpha 7
decreases expression
EXP
bexarotene results in decreased expression of ITGA7 mRNA
CTD
PMID:16648578
NCBI chr 7:1,360,125...1,388,886
Ensembl chr 7:1,359,940...1,388,450
G
Itgb6
integrin subunit beta 6
increases expression
ISO
bexarotene results in increased expression of ITGB6 mRNA
CTD
PMID:17178900
NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671
G
Itih3
inter-alpha trypsin inhibitor, heavy chain 3
decreases expression
EXP
bexarotene results in decreased expression of ITIH3 mRNA
CTD
PMID:16648578
NCBI chr16:6,101,922...6,117,154
Ensembl chr16:6,101,930...6,116,924
G
Itm2a
integral membrane protein 2A
increases expression
ISO
bexarotene results in increased expression of ITM2A mRNA
CTD
PMID:17178900
NCBI chr X:72,486,383...72,492,344
Ensembl chr X:72,486,381...72,492,363
G
Itpr1
inositol 1,4,5-trisphosphate receptor, type 1
increases expression
ISO
bexarotene results in increased expression of ITPR1 mRNA
CTD
PMID:17178900
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
G
Ivl
involucrin
decreases expression
ISO
bexarotene results in decreased expression of IVL mRNA
CTD
PMID:8853895
NCBI chr 2:178,146,694...178,160,807
Ensembl chr 2:178,147,061...178,149,100
G
Jup
junction plakoglobin
increases expression
EXP
bexarotene results in increased expression of JUP mRNA
CTD
PMID:16648578
NCBI chr10:85,300,438...85,327,378
Ensembl chr10:85,300,440...85,327,057
G
Kcnma1
potassium calcium-activated channel subfamily M alpha 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of KCNMA1 mRNA
CTD
PMID:17630414
NCBI chr15:302,480...1,007,675
Ensembl chr15:302,214...1,001,198
G
Kcnt1
potassium sodium-activated channel subfamily T member 1
increases expression
EXP
bexarotene results in increased expression of KCNT1 mRNA
CTD
PMID:16648578
NCBI chr 3:8,682,964...8,736,615
Ensembl chr 3:8,682,113...8,736,667
G
Klf10
KLF transcription factor 10
decreases expression
ISO
bexarotene results in decreased expression of KLF10 mRNA
CTD
PMID:17178900
NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994
G
Klf9
KLF transcription factor 9
increases expression decreases expression
ISO EXP
bexarotene results in increased expression of KLF9 mRNA bexarotene results in decreased expression of KLF9 mRNA
CTD
PMID:16648578 PMID:26096596
NCBI chr 1:220,700,108...220,725,110
Ensembl chr 1:220,700,108...220,725,037
G
Kng1
kininogen 1
decreases expression increases expression
EXP ISO
Bexarotene results in decreased expression of KNG1 mRNA Bexarotene results in increased expression of KNG1 mRNA
CTD
PMID:16648578 PMID:17849452
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
G
Krt14
keratin 14
decreases expression
ISO
bexarotene results in decreased expression of KRT14 mRNA
CTD
PMID:8853895
NCBI chr10:85,137,786...85,142,054
Ensembl chr10:85,066,802...85,171,799
G
Krt15
keratin 15
increases expression
ISO
bexarotene results in increased expression of KRT15 mRNA
CTD
PMID:17178900
NCBI chr10:85,066,797...85,070,614
Ensembl chr10:85,066,802...85,171,799
G
Krt17
keratin 17
decreases expression
ISO
bexarotene results in decreased expression of KRT17 mRNA; bexarotene results in decreased expression of KRT17 protein
CTD
PMID:17178900
NCBI chr10:85,178,673...85,183,392
Ensembl chr10:85,178,675...85,183,392
G
Krt5
keratin 5
decreases expression
ISO
bexarotene results in decreased expression of KRT5 mRNA
CTD
PMID:8853895
NCBI chr 7:132,846,132...132,851,861
Ensembl chr 7:132,846,136...132,851,850
G
Ldhb
lactate dehydrogenase B
decreases expression
EXP
bexarotene results in decreased expression of LDHB mRNA
CTD
PMID:16648578
NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:175,428,385...175,446,403
G
Lgals3
galectin 3
decreases expression
EXP
bexarotene results in decreased expression of LGALS3 mRNA
CTD
PMID:16648578
NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025
G
Lgals5
galectin 5
increases expression
EXP
bexarotene results in increased expression of LGALS5 mRNA
CTD
PMID:16648578
NCBI chr10:63,853,949...63,857,198
Ensembl chr10:63,853,935...63,857,153
G
Lifr
LIF receptor subunit alpha
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of LIFR mRNA
CTD
PMID:17630414
NCBI chr 2:56,224,393...56,292,988
Ensembl chr 2:56,250,120...56,286,699
G
Lipa
lipase A, lysosomal acid type
decreases expression
EXP
bexarotene results in decreased expression of LIP1 mRNA
CTD
PMID:16648578
NCBI chr 1:232,024,351...232,057,735
Ensembl chr 1:232,024,356...232,057,633
G
Lipe
lipase E, hormone sensitive type
decreases expression
EXP
bexarotene results in decreased expression of LIPE mRNA
CTD
PMID:16648578
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
G
Lman1
lectin, mannose-binding, 1
decreases expression
EXP
bexarotene results in decreased expression of LMAN1 mRNA
CTD
PMID:16648578
NCBI chr18:59,508,996...59,530,873
Ensembl chr18:59,508,996...59,530,851
G
Lox
lysyl oxidase
decreases expression
EXP
bexarotene results in decreased expression of LOX mRNA
CTD
PMID:16648578
NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477
G
Loxl2
lysyl oxidase-like 2
increases expression
ISO
bexarotene results in increased expression of LOXL2 mRNA
CTD
PMID:17178900
NCBI chr15:44,683,449...44,773,067
Ensembl chr15:44,683,880...44,773,067
G
Lre3
LINE retrotransposable element 3
increases expression
EXP
bexarotene results in increased expression of LRE3 mRNA
CTD
PMID:16648578
G
Lrg1
leucine-rich alpha-2-glycoprotein 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of LRG1 mRNA
CTD
PMID:17630414
NCBI chr 9:947,516...949,773
Ensembl chr 9:947,516...949,813
G
Lrp2
LDL receptor related protein 2
decreases expression
EXP
bexarotene results in decreased expression of LRP2 mRNA
CTD
PMID:16648578
NCBI chr 3:54,189,305...54,346,769
Ensembl chr 3:54,189,308...54,346,708
G
Lum
lumican
decreases expression
EXP
bexarotene results in decreased expression of LUM mRNA
CTD
PMID:16648578
NCBI chr 7:32,358,990...32,365,794
Ensembl chr 7:32,358,614...32,365,793
G
Lypla1
lysophospholipase 1
decreases expression
EXP
bexarotene results in decreased expression of LYPLA1 mRNA
CTD
PMID:16648578
NCBI chr 5:14,679,605...14,708,774
Ensembl chr 5:14,679,606...14,708,746
G
Lyst
lysosomal trafficking regulator
increases expression
EXP
bexarotene results in increased expression of LYST mRNA
CTD
PMID:17630414
NCBI chr17:86,241,384...86,443,501
Ensembl chr17:86,241,384...86,443,480
G
Lyve1
lymphatic vessel endothelial hyaluronan receptor 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of XLKD1 mRNA
CTD
PMID:17630414
NCBI chr 1:164,962,872...164,976,309
Ensembl chr 1:164,962,872...164,976,309
G
Maf
MAF bZIP transcription factor
increases expression
ISO
bexarotene results in increased expression of MAF mRNA
CTD
PMID:17178900
NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365
G
Maff
MAF bZIP transcription factor F
decreases expression
ISO
bexarotene results in decreased expression of MAFF mRNA
CTD
PMID:17178900
NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851
G
Maob
monoamine oxidase B
decreases expression
EXP
bexarotene results in decreased expression of MAOB mRNA
CTD
PMID:16648578
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
G
Map1b
microtubule-associated protein 1B
increases expression
EXP
bexarotene results in increased expression of MAP1B mRNA
CTD
PMID:16648578
NCBI chr 2:30,817,261...30,910,458
Ensembl chr 2:30,817,261...30,910,317
G
Map2
microtubule-associated protein 2
increases expression
EXP
bexarotene results in increased expression of MAP2 mRNA
CTD
PMID:16648578
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
G
Map3k1
mitogen-activated protein kinase kinase kinase 1
increases expression
EXP
bexarotene results in increased expression of MAP3K1 mRNA
CTD
PMID:16648578
NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463
G
Map3k12
mitogen activated protein kinase kinase kinase 12
increases expression
EXP
bexarotene results in increased expression of MAP3K12 mRNA
CTD
PMID:16648578
NCBI chr 7:133,630,267...133,648,464
Ensembl chr 7:133,630,835...133,640,789
G
Mark1
microtubule affinity regulating kinase 1
increases expression
EXP
bexarotene results in increased expression of MARK1 mRNA
CTD
PMID:16648578
NCBI chr13:96,450,189...96,555,304
Ensembl chr13:96,451,487...96,555,173
G
Me1
malic enzyme 1
increases expression
EXP
bexarotene results in increased expression of ME1 mRNA
CTD
PMID:16648578 PMID:23292798
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
G
Mfsd2a
MFSD2 lysolipid transporter A, lysophospholipid
decreases expression
EXP
bexarotene results in decreased expression of MFSD2A mRNA
CTD
PMID:17630414
NCBI chr 5:135,225,801...135,240,744
Ensembl chr 5:135,225,816...135,240,690
G
Mgp
matrix Gla protein
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of MGP mRNA
CTD
PMID:17630414
NCBI chr 4:169,766,290...169,769,612
Ensembl chr 4:169,766,279...169,769,667
G
Mllt11
MLLT11, transcription factor 7 cofactor
increases expression
ISO
bexarotene results in increased expression of MLLT11 mRNA
CTD
PMID:17178900
NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199
G
Mlxipl
MLX interacting protein-like
multiple interactions
ISO
[Bexarotene co-treated with GW 3965] results in decreased expression of MLXIPL mRNA; [Bexarotene co-treated with T0901317] results in decreased expression of MLXIPL mRNA
CTD
PMID:32123961
NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112
G
Mmp1
matrix metallopeptidase 1
decreases expression
ISO
bexarotene results in decreased expression of MMP1 mRNA
CTD
PMID:17178900
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
G
Mmp14
matrix metallopeptidase 14
decreases expression
EXP
bexarotene results in decreased expression of MMP14 mRNA
CTD
PMID:16648578
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
G
Mrc1
mannose receptor, C type 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of MRC1 mRNA
CTD
PMID:17630414
NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857
G
Mt-co2
mitochondrially encoded cytochrome c oxidase II
decreases expression
ISO
bexarotene results in decreased expression of COX2 mRNA; bexarotene results in decreased expression of COX2 protein
CTD
PMID:17178900
NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689 NCBI chr MT:7,006...7,689
Ensembl chr MT:7,006...7,689
G
Mthfd2
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase
decreases expression
ISO
bexarotene results in decreased expression of MTHFD2 mRNA
CTD
PMID:17178900
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
G
Muc1
mucin 1, cell surface associated
increases expression
EXP
bexarotene results in increased expression of MUC1 mRNA
CTD
PMID:16648578
NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733
G
Mug1
murinoglobulin 1
decreases expression
EXP
bexarotene results in decreased expression of MUG1 mRNA
CTD
PMID:16648578
NCBI chr 4:155,076,270...155,130,051
Ensembl chr 4:155,076,312...155,130,051
G
Napa
NSF attachment protein alpha
increases expression
EXP
bexarotene results in increased expression of NAPA mRNA
CTD
PMID:16648578
NCBI chr 1:76,787,036...76,805,869
Ensembl chr 1:76,786,932...76,805,869
G
Nat8
N-acetyltransferase 8
decreases expression
EXP
bexarotene results in decreased expression of NAT8 mRNA
CTD
PMID:17630414
NCBI chr 4:118,279,521...118,284,671
Ensembl chr 4:118,270,954...118,281,763
G
Ndufaf3
NADH:ubiquinone oxidoreductase complex assembly factor 3
increases expression
EXP
bexarotene results in increased expression of NDUFAF3 mRNA
CTD
PMID:16648578
NCBI chr 8:109,261,362...109,263,194
Ensembl chr 8:109,261,363...109,263,194
G
Neurod2
neuronal differentiation 2
increases expression
EXP
bexarotene results in increased expression of NEUROD2 mRNA
CTD
PMID:16648578
NCBI chr10:83,323,801...83,327,986
Ensembl chr10:83,324,442...83,327,986
G
Nim1k
NIM1 serine/threonine protein kinase
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of NIM1K mRNA
CTD
PMID:17630414
NCBI chr 2:51,670,764...51,714,782
Ensembl chr 2:51,670,772...51,714,762
G
Nol3
nucleolar protein 3
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of NOL3 mRNA
CTD
PMID:17630414
NCBI chr19:33,154,061...33,158,250
Ensembl chr19:33,154,062...33,158,250
G
Nos2
nitric oxide synthase 2
decreases expression
ISO
bexarotene results in decreased expression of NOS2 mRNA
CTD
PMID:17849452
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
G
Npy
neuropeptide Y
increases expression
EXP
bexarotene results in increased expression of NPY mRNA
CTD
PMID:17630414
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
G
Nr0b2
nuclear receptor subfamily 0, group B, member 2
increases expression multiple interactions
EXP ISO
bexarotene results in increased expression of NR0B2 mRNA Bexarotene results in increased expression of NR0B2 mRNA [Bexarotene co-treated with GW 3965] results in increased expression of NR0B2 mRNA; [Bexarotene co-treated with paxilline] results in increased expression of NR0B2 mRNA; [Bexarotene co-treated with T0901317] results in increased expression of NR0B2 mRNA
CTD
PMID:17630414 PMID:23292798 PMID:32123961
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
G
Nr1h3
nuclear receptor subfamily 1, group H, member 3
multiple interactions decreases expression
ISO
[Bexarotene co-treated with GW 3965] results in increased expression of NR1H3 mRNA; [Bexarotene co-treated with paxilline] results in increased expression of NR1H3 mRNA; [Bexarotene co-treated with T0901317] results in increased expression of NR1H3 mRNA; Bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA] Bexarotene results in decreased expression of NR1H3 mRNA
CTD
PMID:25932594 PMID:32123961
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
G
Nr1i3
nuclear receptor subfamily 1, group I, member 3
increases expression multiple interactions
EXP ISO
bexarotene results in increased expression of NR1I3 mRNA Bexarotene binds to and results in increased activity of NR1I3 protein alternative form
CTD
PMID:17630414 PMID:31312845
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
G
Nrip1
nuclear receptor interacting protein 1
multiple interactions
ISO
[Bexarotene co-treated with GW 3965] results in increased expression of NRIP1 mRNA; [Bexarotene co-treated with T0901317] results in increased expression of NRIP1 mRNA
CTD
PMID:32123961
NCBI chr11:14,895,843...14,979,490
Ensembl chr11:14,895,553...14,981,761
G
Oaz1
ornithine decarboxylase antizyme 1
increases expression
EXP
bexarotene results in increased expression of OAZ1 mRNA
CTD
PMID:16648578
NCBI chr 7:8,883,855...8,886,315
Ensembl chr 7:8,883,851...8,886,310
G
Odc1
ornithine decarboxylase 1
decreases expression
ISO
bexarotene results in decreased expression of ODC1 mRNA
CTD
PMID:17178900
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
G
Or8g20b
olfactory receptor family 8 subfamily G member 20B
increases expression
EXP
Bexarotene results in increased expression of OR8G20B mRNA
CTD
PMID:16648578
NCBI chr 8:39,282,393...39,283,352
Ensembl chr 8:39,282,325...39,292,365
G
Orm1
orosomucoid 1
decreases expression
EXP
bexarotene results in decreased expression of ORM1 mRNA
CTD
PMID:16648578
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
G
P4hb
prolyl 4-hydroxylase subunit beta
increases expression
EXP
bexarotene results in increased expression of P4HB mRNA
CTD
PMID:16648578
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
G
Pde2a
phosphodiesterase 2A
decreases expression
EXP
bexarotene results in decreased expression of PDE2A mRNA
CTD
PMID:16648578
NCBI chr 1:155,823,590...155,915,434
Ensembl chr 1:155,813,180...155,915,434
G
Pdk2
pyruvate dehydrogenase kinase 2
increases expression
EXP
bexarotene results in increased expression of PDK2 mRNA
CTD
PMID:16648578
NCBI chr10:79,972,550...79,987,074
Ensembl chr10:79,972,556...79,987,085
G
Pdk4
pyruvate dehydrogenase kinase 4
increases expression
EXP
bexarotene results in increased expression of PDK4 mRNA
CTD
PMID:16648578
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
G
Per2
period circadian regulator 2
decreases expression
ISO
bexarotene results in decreased expression of PER2 mRNA
CTD
PMID:17178900
NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459
G
Pex11a
peroxisomal biogenesis factor 11 alpha
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of PEX11A mRNA
CTD
PMID:17630414
NCBI chr 1:133,680,091...133,687,172
Ensembl chr 1:133,680,091...133,687,172
G
Pex19
peroxisomal biogenesis factor 19
decreases expression
EXP
bexarotene results in decreased expression of PEX19 mRNA
CTD
PMID:16648578
NCBI chr13:84,592,277...84,608,793
Ensembl chr13:84,592,312...84,608,608
G
Pf4
platelet factor 4
increases expression
EXP
bexarotene results in increased expression of PF4 mRNA
CTD
PMID:17630414
NCBI chr14:17,298,304...17,299,220
Ensembl chr14:17,298,308...17,299,365
G
Pgr
progesterone receptor
multiple interactions
ISO
bexarotene binds to and results in decreased activity of PGR protein
CTD
PMID:25752796
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
G
Pik3cb
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta
increases expression
EXP
bexarotene results in increased expression of PIK3CB mRNA
CTD
PMID:16648578
NCBI chr 8:99,594,600...99,699,772
Ensembl chr 8:99,594,644...99,699,663
G
Pik3r1
phosphoinositide-3-kinase regulatory subunit 1
multiple interactions
ISO
bexarotene promotes the reaction [rosiglitazone results in increased expression of PIK3R1 mRNA]
CTD
PMID:10548525
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
G
Pik3r3
phosphoinositide-3-kinase regulatory subunit 3
increases expression
EXP
bexarotene results in increased expression of PIK3R3 mRNA
CTD
PMID:16648578
NCBI chr 5:129,700,925...129,772,591
Ensembl chr 5:129,701,229...129,772,583
G
Pkib
cAMP-dependent protein kinase inhibitor beta
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of PKIB mRNA
CTD
PMID:17630414
NCBI chr20:36,965,172...37,062,190
Ensembl chr20:36,905,340...37,062,187
G
Plagl1
PLAG1 like zinc finger 1
decreases expression
EXP
bexarotene results in decreased expression of PLAGL1 mRNA
CTD
PMID:16648578
NCBI chr 1:7,477,295...7,517,229
Ensembl chr 1:7,477,177...7,517,228
G
Plat
plasminogen activator, tissue type
increases expression
ISO
bexarotene results in increased expression of PLAT mRNA
CTD
PMID:17178900
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
G
Plaur
plasminogen activator, urokinase receptor
decreases expression
ISO
bexarotene results in decreased expression of PLAUR mRNA
CTD
PMID:17178900
NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595
G
Plin1
perilipin 1
increases expression
ISO
bexarotene results in increased expression of PLIN1 mRNA
CTD
PMID:25932594
NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828
G
Plod2
procollagen lysine, 2-oxoglutarate 5-dioxygenase 2
increases expression
ISO
bexarotene results in increased expression of PLOD2 mRNA
CTD
PMID:17178900
NCBI chr 8:93,084,548...93,167,255
Ensembl chr 8:93,084,513...93,167,255
G
Pno1
partner of NOB1 homolog
decreases expression
ISO
bexarotene results in decreased expression of PNO1 mRNA
CTD
PMID:17178900
NCBI chr14:91,609,711...91,618,280
Ensembl chr14:91,609,233...91,618,324
G
Pnrc1
proline-rich nuclear receptor coactivator 1
increases expression
ISO
bexarotene results in increased expression of PNRC1 mRNA
CTD
PMID:17178900
NCBI chr 5:47,647,070...47,657,832
Ensembl chr 5:47,647,071...47,650,161
G
Pola1
DNA polymerase alpha 1, catalytic subunit
increases expression
EXP
bexarotene results in increased expression of POLA1 mRNA
CTD
PMID:16648578
NCBI chr X:58,034,617...58,348,612
Ensembl chr X:58,034,619...58,348,536
G
Pon1
paraoxonase 1
decreases expression
EXP
bexarotene results in decreased expression of PON1 mRNA
CTD
PMID:16648578
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
G
Por
cytochrome p450 oxidoreductase
increases expression
EXP
bexarotene results in increased expression of POR mRNA
CTD
PMID:16648578
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
G
Ppp2cb
protein phosphatase 2 catalytic subunit beta
increases expression
EXP
bexarotene results in increased expression of PPP2CB mRNA
CTD
PMID:16648578
NCBI chr16:58,558,119...58,579,325
Ensembl chr16:58,558,122...58,579,576
G
Ppp2r1a
protein phosphatase 2 scaffold subunit A alpha
increases expression
EXP
bexarotene results in increased expression of PPP2R1A mRNA
CTD
PMID:16648578
NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129
G
Ppt1
palmitoyl-protein thioesterase 1
decreases expression
EXP
bexarotene results in decreased expression of PPT1 mRNA
CTD
PMID:16648578
NCBI chr 5:135,121,164...135,142,048
Ensembl chr 5:135,121,163...135,142,048
G
Prdx6
peroxiredoxin 6
increases expression
EXP
bexarotene results in increased expression of PRDX6 mRNA
CTD
PMID:16648578
NCBI chr13:73,528,746...73,539,295
Ensembl chr13:73,528,210...73,539,355
G
Prkar2b
protein kinase cAMP-dependent type II regulatory subunit beta
decreases expression
EXP
bexarotene results in decreased expression of PRKAR2B mRNA
CTD
PMID:16648578
NCBI chr 6:48,563,659...48,653,933
Ensembl chr 6:48,563,662...48,653,933
G
Prl8a4
prolactin family 8, subfamily A, member 4
increases expression
EXP
bexarotene results in increased expression of PRL8A4 mRNA
CTD
PMID:16648578
NCBI chr17:37,429,960...37,436,053
Ensembl chr17:37,429,960...37,436,053
G
Prlhr
prolactin releasing hormone receptor
increases expression
EXP
bexarotene results in increased expression of PRLHR mRNA
CTD
PMID:16648578
NCBI chr 1:259,606,704...259,608,391
Ensembl chr 1:259,606,704...259,608,391
G
Prlr
prolactin receptor
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of PRLR mRNA
CTD
PMID:17630414
NCBI chr 2:59,134,147...59,324,719
Ensembl chr 2:59,134,588...59,324,718
G
Prnp
prion protein
decreases expression
EXP
bexarotene results in decreased expression of PRNP mRNA
CTD
PMID:16648578
NCBI chr 3:119,186,073...119,201,513
Ensembl chr 3:119,177,485...119,203,937
G
Prom1
prominin 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of PROM1 mRNA
CTD
PMID:17630414
NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527
G
Prr15
proline rich 15
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of PRR15 mRNA
CTD
PMID:17630414
NCBI chr 4:83,432,002...83,435,582
Ensembl chr 4:83,431,758...83,437,436
G
Psap
prosaposin
increases expression
EXP
bexarotene results in increased expression of PSAP mRNA
CTD
PMID:16648578
NCBI chr20:28,214,229...28,240,501
Ensembl chr20:28,214,271...28,240,498
G
Psmc2
proteasome 26S subunit, ATPase 2
increases expression
EXP
bexarotene results in increased expression of PSMC2 mRNA
CTD
PMID:16648578
NCBI chr 4:13,255,850...13,270,160
Ensembl chr 4:13,255,856...13,270,185
G
Psmd4
proteasome 26S subunit ubiquitin receptor, non-ATPase 4
increases expression
EXP
bexarotene results in increased expression of PSMD4 mRNA
CTD
PMID:16648578
NCBI chr 2:182,598,934...182,608,250
Ensembl chr 2:182,598,934...182,608,194
G
Pspn
persephin
increases expression
EXP
bexarotene results in increased expression of PSPN mRNA
CTD
PMID:16648578
NCBI chr 9:1,840,906...1,841,748
Ensembl chr 9:1,840,896...1,854,327
G
Ptger3
prostaglandin E receptor 3
decreases expression
ISO
bexarotene results in decreased expression of PTGER3 mRNA
CTD
PMID:17849452
NCBI chr 2:246,606,131...246,750,970
Ensembl chr 2:246,606,183...246,684,434
G
Ptger4
prostaglandin E receptor 4
decreases expression
ISO
bexarotene results in decreased expression of PTGER4 mRNA
CTD
PMID:17849452
NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670
G
Ptms
parathymosin
increases expression
EXP
bexarotene results in increased expression of PTMS mRNA
CTD
PMID:16648578
NCBI chr 4:157,722,384...157,726,575
Ensembl chr 4:157,722,386...157,727,009
G
Ptprc
protein tyrosine phosphatase, receptor type, C
increases expression
EXP
bexarotene results in increased expression of PTPRC mRNA
CTD
PMID:16648578
NCBI chr13:49,596,193...49,708,283
Ensembl chr13:49,596,193...49,708,692
G
Qpct
glutaminyl-peptide cyclotransferase
increases expression
EXP
bexarotene results in increased expression of QPCT mRNA
CTD
PMID:16648578
NCBI chr 6:15,964,656...15,996,730
Ensembl chr 6:15,964,657...15,996,711
G
Rab11b
RAB11B, member RAS oncogene family
increases expression
EXP
bexarotene results in increased expression of RAB11B mRNA
CTD
PMID:16648578
NCBI chr 7:14,521,448...14,534,589
Ensembl chr 7:14,521,368...14,534,593
G
Rab7a
RAB7A, member RAS oncogene family
increases expression
EXP
bexarotene results in increased expression of RAB7 mRNA
CTD
PMID:16648578
NCBI chr 4:120,461,966...120,510,756
Ensembl chr 4:120,461,963...120,506,889
G
Rabep2
rabaptin, RAB GTPase binding effector protein 2
increases expression
EXP
bexarotene results in increased expression of RABEP2 mRNA
CTD
PMID:16648578
NCBI chr 1:181,010,305...181,026,651
Ensembl chr 1:181,010,305...181,026,648
G
Rarb
retinoic acid receptor, beta
increases expression multiple interactions
ISO
Bexarotene results in increased expression of RARB mRNA CD2665 promotes the reaction [Bexarotene results in increased expression of RARB mRNA]; UVI 3003 inhibits the reaction [Bexarotene results in increased expression of RARB mRNA]
CTD
PMID:17178900 PMID:35483669
NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
G
Rasl11a
RAS-like family 11 member A
increases expression
EXP
bexarotene results in increased expression of RASL11A mRNA
CTD
PMID:16648578
NCBI chr12:8,258,148...8,260,909
Ensembl chr12:8,258,159...8,262,576
G
Rassf1
Ras association domain family member 1
decreases expression
ISO
bexarotene results in decreased expression of RASSF1 mRNA
CTD
PMID:17849452
NCBI chr 8:108,225,023...108,236,164
Ensembl chr 8:108,225,023...108,236,164
G
Rb1
RB transcriptional corepressor 1
decreases phosphorylation
ISO
bexarotene results in decreased phosphorylation of RB1 protein
CTD
PMID:16273314
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
G
Rdh16
retinol dehydrogenase 16
increases expression
EXP
bexarotene results in increased expression of RDH2 mRNA
CTD
PMID:16648578
NCBI chr 7:63,616,711...63,625,053
Ensembl chr 7:63,597,536...63,624,124
G
Renbp
renin binding protein
increases expression
EXP
bexarotene results in increased expression of RENBP mRNA
CTD
PMID:16648578
NCBI chr X:151,661,463...151,670,538
Ensembl chr X:151,661,458...151,670,516
G
Rest
RE1-silencing transcription factor
increases expression
EXP
bexarotene results in increased expression of REST mRNA
CTD
PMID:16648578
NCBI chr14:30,859,109...30,879,828
Ensembl chr14:30,862,553...30,894,354
G
Rgn
regucalcin
decreases expression
EXP
bexarotene results in decreased expression of RGN mRNA
CTD
PMID:16648578
NCBI chr X:1,619,030...1,634,456
Ensembl chr X:1,619,032...1,634,450
G
Rida
reactive intermediate imine deaminase A homolog
decreases expression
EXP
bexarotene results in decreased expression of RIDA mRNA
CTD
PMID:16648578
NCBI chr 7:65,691,429...65,705,257
Ensembl chr 7:65,691,435...65,705,716
G
Rnase1
ribonuclease A family member 1, pancreatic
increases expression
EXP
Bexarotene results in increased expression of RNASE1 mRNA
CTD
PMID:16648578
NCBI chr15:24,361,924...24,363,633
Ensembl chr15:24,361,927...24,363,624
G
Rpl18a
ribosomal protein L18A
increases expression
EXP
bexarotene results in increased expression of RPL18A mRNA
CTD
PMID:16648578
NCBI chr16:18,542,555...18,544,578
Ensembl chr16:18,542,566...18,545,546
G
Rpl22
ribosomal protein L22
increases expression
EXP
bexarotene results in increased expression of RPL22 mRNA
CTD
PMID:16648578
NCBI chr 5:162,835,241...162,843,394
Ensembl chr 5:162,833,740...162,843,368 Ensembl chr 7:162,833,740...162,843,368 Ensembl chr 4:162,833,740...162,843,368
G
Rpl7a
ribosomal protein L7A
increases expression
EXP
bexarotene results in increased expression of RPL7A mRNA
CTD
PMID:16648578
NCBI chr 3:10,239,026...10,241,703
Ensembl chr 3:10,239,001...10,241,716
G
Rps2
ribosomal protein S2
increases expression
EXP
bexarotene results in increased expression of RPS2 mRNA
CTD
PMID:16648578
NCBI chr10:13,747,316...13,749,165
Ensembl chr10:13,747,301...13,749,163
G
Rpsa
ribosomal protein SA
increases expression
EXP
bexarotene results in increased expression of RPSA mRNA
CTD
PMID:16648578
NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247
G
RT1-Ba
RT1 class II, locus Ba
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of RT1-BA mRNA
CTD
PMID:17630414
NCBI chr20:4,575,134...4,579,727
Ensembl chr20:4,575,134...4,579,744
G
RT1-Cl
RT1 class Ib, locus Cl
increases expression
EXP
bexarotene results in increased expression of RT1-CL mRNA
CTD
PMID:16648578
G
RT1-Da
RT1 class II, locus Da
multiple interactions increases expression
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of RT1-DA mRNA bexarotene results in increased expression of RT1-DA mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr20:4,513,464...4,518,457
Ensembl chr20:4,512,911...4,518,455
G
RT1-Db1
RT1 class II, locus Db1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in decreased expression of RT1-DB1 mRNA
CTD
PMID:17630414
NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258
G
Rtn4
reticulon 4
increases expression
EXP
bexarotene results in increased expression of RTN4 mRNA
CTD
PMID:17630414
NCBI chr14:103,450,074...103,497,687
Ensembl chr14:103,449,930...103,497,686
G
Rxra
retinoid X receptor alpha
affects binding multiple interactions
ISO
Bexarotene binds to RXRA protein Bexarotene binds to and results in increased activity of RXRA protein; RXRA promotes the reaction [Bexarotene results in increased expression of APOA2 mRNA]; RXRA protein affects the reaction [Bexarotene results in increased expression of CYP2B6 mRNA]; RXRA protein affects the reaction [Bexarotene results in increased expression of HSD11B2 mRNA]; RXRA protein affects the reaction [Bexarotene results in increased expression of HSD11B2 protein]
CTD
PMID:8668150 PMID:21218783 PMID:23843199 PMID:31312845 PMID:31566444 PMID:31927052 More...
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
G
Rxrb
retinoid X receptor beta
affects binding
ISO
bexarotene binds to RXRB protein
CTD
PMID:23843199
NCBI chr20:4,816,813...4,823,267
Ensembl chr20:4,816,815...4,828,773
G
Rxrg
retinoid X receptor gamma
affects binding decreases expression
ISO
bexarotene binds to RXRG protein bexarotene results in decreased expression of RXRG mRNA
CTD
PMID:17849452 PMID:23843199
NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167
G
S100a10
S100 calcium binding protein A10
decreases expression
EXP
bexarotene results in decreased expression of S100A10 mRNA
CTD
PMID:16648578
NCBI chr 2:179,221,012...179,229,659
Ensembl chr 2:179,220,887...179,229,661
G
S100a9
S100 calcium binding protein A9
increases expression
ISO EXP
bexarotene results in increased expression of S100A9 mRNA
CTD
PMID:16648578 PMID:17178900
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
G
S100b
S100 calcium binding protein B
decreases expression
EXP
bexarotene results in decreased expression of S100B mRNA
CTD
PMID:16648578
NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
G
Saal1
serum amyloid A-like 1
increases expression
EXP
Bexarotene results in increased expression of SAA2 mRNA
CTD
PMID:16648578
NCBI chr 1:97,198,685...97,218,131
Ensembl chr 1:97,198,800...97,222,156
G
Scd
stearoyl-CoA desaturase
increases expression multiple interactions
ISO EXP
bexarotene results in increased expression of SCD1 mRNA Bexarotene results in increased expression of SCD mRNA [Tamoxifen co-treated with bexarotene] results in increased expression of SCD1 mRNA [Bexarotene co-treated with GW 3965] results in increased expression of SCD mRNA; [Bexarotene co-treated with T0901317] results in increased expression of SCD mRNA
CTD
PMID:17178900 PMID:17630414 PMID:23292798 PMID:32123961
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
G
Scd2
stearoyl-Coenzyme A desaturase 2
increases expression
EXP
bexarotene results in increased expression of SCD2 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr 1:243,169,171...243,182,231
Ensembl chr 1:243,169,236...243,182,232
G
Scp2
sterol carrier protein 2
decreases expression
EXP
bexarotene results in decreased expression of SCP2 mRNA
CTD
PMID:16648578
NCBI chr 5:122,806,949...122,881,259
Ensembl chr 5:122,776,549...122,881,287
G
Sdc2
syndecan 2
decreases expression
EXP
bexarotene results in decreased expression of SDC2 mRNA
CTD
PMID:16648578
NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081
G
Serpina1
serpin family A member 1
decreases expression
EXP
bexarotene results in decreased expression of SERPINA1 mRNA
CTD
PMID:16648578
NCBI chr 6:122,866,314...122,888,339
Ensembl chr 6:122,866,312...122,888,339
G
Serpina3n
serine (or cysteine) peptidase inhibitor, clade A, member 3N
decreases expression
EXP
bexarotene results in decreased expression of SERPINA3N mRNA
CTD
PMID:16648578
NCBI chr 6:123,323,623...123,331,181
Ensembl chr 6:123,323,629...123,332,433
G
Serpind1
serpin family D member 1
decreases expression
EXP
bexarotene results in decreased expression of SERPIND1 mRNA
CTD
PMID:16648578
NCBI chr11:83,664,517...83,675,593
Ensembl chr11:83,664,518...83,675,519
G
Serpinh1
serpin family H member 1
increases expression
EXP
bexarotene results in increased expression of SERPINH1 mRNA
CTD
PMID:17630414
NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801
G
Sfpq
splicing factor proline and glutamine rich
decreases expression
EXP
bexarotene results in decreased expression of SFPQ mRNA
CTD
PMID:16648578
NCBI chr 5:139,338,034...139,353,476
Ensembl chr 5:139,338,075...139,353,472
G
Shh
sonic hedgehog signaling molecule
increases expression
ISO
bexarotene results in increased expression of SHH mRNA
CTD
PMID:26096596
NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170
G
Siah2
siah E3 ubiquitin protein ligase 2
decreases expression
ISO
bexarotene results in decreased expression of SIAH2 mRNA
CTD
PMID:17178900
NCBI chr 2:142,913,924...142,931,752
Ensembl chr 2:142,914,003...142,931,950
G
Slc1a3
solute carrier family 1 member 3
decreases expression
EXP
bexarotene results in decreased expression of SLC1A3 mRNA
CTD
PMID:16648578
NCBI chr 2:57,755,495...57,830,605
Ensembl chr 2:57,755,497...57,830,605
G
Slc27a1
solute carrier family 27 member 1
increases expression multiple interactions
EXP ISO
bexarotene results in increased expression of SLC27A1 mRNA [[Dexamethasone co-treated with INS protein co-treated with 1-Methyl-3-isobutylxanthine] co-treated with bexarotene] results in increased expression of SLC27A1 mRNA
CTD
PMID:10777552
NCBI chr16:18,278,984...18,300,173
Ensembl chr16:18,278,984...18,296,063
G
Slc27a2
solute carrier family 27 member 2
decreases expression
EXP
bexarotene results in decreased expression of SLC27A2 mRNA
CTD
PMID:16648578
NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208
G
Slc2a2
solute carrier family 2 member 2
increases expression
EXP
bexarotene results in increased expression of SLC2A2 mRNA
CTD
PMID:16648578
NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
G
Slc2a4
solute carrier family 2 member 4
multiple interactions
ISO
[bexarotene co-treated with rosiglitazone] results in increased expression of SLC2A4 mRNA
CTD
PMID:10548525
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
G
Slc35b1
solute carrier family 35, member B1
increases expression
EXP
bexarotene results in increased expression of SLC35B1 mRNA
CTD
PMID:16648578
NCBI chr10:80,327,921...80,335,279
Ensembl chr10:80,327,945...80,335,274
G
Slc6a6
solute carrier family 6 member 6
increases expression
EXP
bexarotene results in increased expression of SLC6A6 mRNA
CTD
PMID:16648578
NCBI chr 4:124,195,186...124,268,880
Ensembl chr 4:124,195,218...124,268,875
G
Slc7a1
solute carrier family 7 member 1
decreases expression
ISO
bexarotene results in decreased expression of SLC7A1 mRNA
CTD
PMID:17178900
NCBI chr12:6,628,288...6,703,849
Ensembl chr12:6,628,007...6,703,849
G
Slc7a5
solute carrier family 7 member 5
decreases expression
ISO
bexarotene results in decreased expression of SLC7A5 mRNA
CTD
PMID:17178900
NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823
G
Smad5
SMAD family member 5
increases expression
ISO
bexarotene results in increased expression of SMAD5 mRNA
CTD
PMID:17178900
NCBI chr17:7,862,332...7,891,678
Ensembl chr17:7,864,720...7,891,634
G
Sncg
synuclein, gamma
decreases expression
EXP
bexarotene results in decreased expression of SNCG mRNA
CTD
PMID:16648578
NCBI chr16:9,700,513...9,705,751
Ensembl chr16:9,700,514...9,705,368
G
Snd1
staphylococcal nuclease and tudor domain containing 1
increases expression
EXP
bexarotene results in increased expression of SND1 mRNA
CTD
PMID:16648578
NCBI chr 4:57,095,205...57,494,501
Ensembl chr 4:57,095,208...57,530,843
G
Snn
stannin
decreases expression
EXP
bexarotene results in decreased expression of SNN mRNA
CTD
PMID:16648578
NCBI chr10:4,572,933...4,581,606
Ensembl chr10:4,572,376...4,584,021
G
Sord
sorbitol dehydrogenase
decreases expression
EXP
bexarotene results in decreased expression of SORD mRNA
CTD
PMID:16648578
NCBI chr 3:109,184,697...109,216,133
Ensembl chr 3:109,184,676...109,216,133
G
Sorl1
sortilin related receptor 1
multiple interactions
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of SORL1 mRNA
CTD
PMID:17630414
NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513
G
Sp7
Sp7 transcription factor
decreases expression multiple interactions
ISO
bexarotene results in decreased expression of SP7 mRNA bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]
CTD
PMID:25932594
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
G
Sparc
secreted protein acidic and cysteine rich
increases expression
ISO
bexarotene results in increased expression of SPARC mRNA
CTD
PMID:17178900
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
G
Spink1
serine peptidase inhibitor, Kazal type 1
multiple interactions increases expression
EXP
[bexarotene co-treated with Tamoxifen] results in increased expression of SPINK1 mRNA bexarotene results in increased expression of SPINK1 mRNA
CTD
PMID:16648578 PMID:17630414
NCBI chr18:35,870,723...35,882,693
Ensembl chr18:35,824,550...35,882,642
G
Spmip11
sperm microtubule inner protein 11
multiple interactions
EXP
[Bexarotene co-treated with Tamoxifen] results in increased expression of SPMIP11 mRNA
CTD
PMID:17630414
NCBI chr 7:129,720,950...129,742,485
Ensembl chr 7:129,720,950...129,742,485
G
Spp1
secreted phosphoprotein 1
decreases expression
EXP
bexarotene results in decreased expression of SPP1 mRNA
CTD
PMID:16648578
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
G
Spp2
secreted phosphoprotein 2
decreases expression
EXP
bexarotene results in decreased expression of SPP2 mRNA
CTD
PMID:16648578
NCBI chr 9:89,006,858...89,026,676
Ensembl chr 9:89,007,175...89,026,688
G
Spt1
salivary protein 1
decreases expression
EXP
bexarotene results in decreased expression of SPT1 mRNA
CTD
PMID:16648578
NCBI chr 7:134,914,177...134,924,215
Ensembl chr 7:134,914,177...134,924,157
G
Sqstm1
sequestosome 1
increases expression
EXP
bexarotene results in increased expression of SQSTM1 mRNA
CTD
PMID:16648578
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
G
Srd5a1
steroid 5 alpha-reductase 1
decreases expression
EXP
bexarotene results in decreased expression of SRD5A1 mRNA
CTD
PMID:16648578
NCBI chr 1:33,686,069...33,720,468
Ensembl chr 1:33,686,391...33,720,461
G
Srebf1
sterol regulatory element binding transcription factor 1
increases expression multiple interactions
EXP ISO
bexarotene results in increased expression of SREBF1 mRNA [Bexarotene co-treated with GW 3965] results in increased expression of SREBF1 mRNA; [Bexarotene co-treated with paxilline] results in increased expression of SREBF1 mRNA; [Bexarotene co-treated with T0901317] results in increased expression of SREBF1 mRNA; Bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA] Bexarotene results in increased expression of SREBF1 mRNA
CTD
PMID:23292798 PMID:25932594 PMID:32123961
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
G
Srsf2
serine and arginine rich splicing factor 2
decreases expression
ISO
bexarotene results in decreased expression of SRSF2 mRNA
CTD
PMID:17178900
NCBI chr10:102,052,158...102,055,365
Ensembl chr10:102,052,314...102,055,338
G
Sult1a1
sulfotransferase family 1A member 1
decreases expression
EXP
bexarotene results in decreased expression of SULT1A1 mRNA
CTD
PMID:16648578
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
G
Sult1b1
sulfotransferase family 1B member 1
decreases expression
EXP
bexarotene results in decreased expression of SULT1B1 mRNA
CTD
PMID:16648578
NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483
G
Sult2a1
sulfotransferase family 2A member 1
decreases expression
EXP
bexarotene results in decreased expression of SULT2A1 mRNA
CTD
PMID:16648578
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
G
Tacr2
tachykinin receptor 2
increases expression
EXP
bexarotene results in increased expression of TACR2 mRNA
CTD
PMID:16648578
NCBI chr20:30,208,907...30,223,446
Ensembl chr20:30,208,907...30,223,446
G
Tecr
trans-2,3-enoyl-CoA reductase
increases expression
EXP
bexarotene results in increased expression of TECR mRNA
CTD
PMID:16648578
NCBI chr19:24,526,700...24,568,168
Ensembl chr19:24,541,615...24,568,168
G
Tf
transferrin
increases expression
EXP
bexarotene results in increased expression of TF mRNA
CTD
PMID:16648578
NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
G
Tg
thyroglobulin
increases expression
EXP
bexarotene results in increased expression of TG mRNA
CTD
PMID:16648578
NCBI chr 7:98,418,293...98,603,210
Ensembl chr 7:98,418,293...98,603,210
G
Tgfb3
transforming growth factor, beta 3
increases expression
EXP
bexarotene results in increased expression of TGFB3 mRNA
CTD
PMID:16648578
NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564
G
Tgm1
transglutaminase 1
decreases expression
ISO
bexarotene results in decreased expression of TGM1 mRNA
CTD
PMID:8853895
NCBI chr15:29,191,039...29,206,000
Ensembl chr15:29,191,041...29,204,523
G
Tgm2
transglutaminase 2
increases expression multiple interactions
ISO
bexarotene results in increased expression of TGM2 mRNA diazepinylbenzoic acid inhibits the reaction [bexarotene results in increased expression of TGM2 mRNA]
CTD
PMID:17178900 PMID:21622945 PMID:25932594
NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981
G
Thra
thyroid hormone receptor alpha
multiple interactions
ISO
bexarotene binds to and results in decreased activity of THRA protein
CTD
PMID:25752796
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
G
Tm4sf1
transmembrane 4 L six family member 1
increases expression
ISO
bexarotene results in increased expression of TM4SF1 mRNA
CTD
PMID:17178900
NCBI chr 2:141,456,950...141,466,146
Ensembl chr 2:141,453,310...141,466,146
G
Tmed2
transmembrane p24 trafficking protein 2
increases expression
EXP
bexarotene results in increased expression of TMED2 mRNA
CTD
PMID:16648578
NCBI chr12:32,052,542...32,061,628
Ensembl chr12:32,052,543...32,071,903
G
Tnfrsf1a
TNF receptor superfamily member 1A
increases expression
EXP
bexarotene results in increased expression of TNFRSF1A mRNA
CTD
PMID:16648578
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
G
Tns1
tensin 1
increases expression
EXP
bexarotene results in increased expression of TNS1 mRNA
CTD
PMID:16648578
NCBI chr 9:75,491,886...75,702,853
Ensembl chr 9:75,495,814...75,703,225
G
Tp53
tumor protein p53
multiple interactions
ISO
bexarotene results in increased phosphorylation of and results in increased activity of TP53 protein
CTD
PMID:19067706
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
G
Tp73
tumor protein p73
increases expression
ISO
bexarotene results in increased expression of TP73 protein
CTD
PMID:19067706
NCBI chr 5:164,621,377...164,703,958
Ensembl chr 5:164,621,377...164,681,128
G
Tpm1
tropomyosin 1
increases expression
EXP
bexarotene results in increased expression of TPM1 mRNA
CTD
PMID:16648578
NCBI chr 8:67,635,479...67,662,330
Ensembl chr 8:67,635,479...67,662,802
G
Tpm3
tropomyosin 3
increases expression
EXP
bexarotene results in increased expression of TPM3 mRNA
CTD
PMID:16648578
NCBI chr 2:175,517,198...175,545,014
Ensembl chr 2:175,517,226...175,545,013
G
Tpm4
tropomyosin 4
increases expression
EXP
bexarotene results in increased expression of TPM4 mRNA
CTD
PMID:16648578
NCBI chr16:17,684,415...17,698,456
Ensembl chr16:17,683,195...17,705,984
G
Tsc22d3
TSC22 domain family, member 3
increases expression
ISO
bexarotene results in increased expression of TSC22D3 mRNA
CTD
PMID:17178900
NCBI chr X:104,217,898...104,277,886
Ensembl chr X:104,217,925...104,276,861
G
Ttr
transthyretin
decreases expression
EXP
bexarotene results in decreased expression of TTR mRNA
CTD
PMID:16648578
NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008
G
Tuba1a
tubulin, alpha 1A
increases expression
EXP
bexarotene results in increased expression of TUBA1A mRNA
CTD
PMID:16648578
NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
G
Uap1
UDP-N-acetylglucosamine pyrophosphorylase 1
decreases expression
ISO
bexarotene results in decreased expression of UAP1 mRNA
CTD
PMID:17178900
NCBI chr13:82,342,946...82,377,558
Ensembl chr13:82,342,946...82,377,469
G
Ucp2
uncoupling protein 2
multiple interactions
ISO
bexarotene promotes the reaction [rosiglitazone results in increased expression of UCP2 mRNA]
CTD
PMID:10548525
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
G
Ugt2b
UDP glycosyltransferase 2 family, polypeptide B
decreases expression
EXP
bexarotene results in decreased expression of UGT2B mRNA
CTD
PMID:16648578
NCBI chr14:20,630,572...20,665,062
Ensembl chr14:20,630,250...20,651,776
G
Vamp8
vesicle-associated membrane protein 8
increases expression
ISO
bexarotene results in increased expression of VAMP8 mRNA
CTD
PMID:17178900
NCBI chr 4:104,442,383...104,452,884
Ensembl chr 4:104,442,393...104,452,897
G
Vegfa
vascular endothelial growth factor A
increases expression
EXP
bexarotene results in increased expression of VEGFA mRNA
CTD
PMID:16648578
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
G
Xbp1
X-box binding protein 1
decreases expression
ISO
bexarotene results in decreased expression of XBP1 mRNA
CTD
PMID:17178900
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
G
Ywhah
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta
decreases expression
EXP
bexarotene results in decreased expression of YWHAH mRNA
CTD
PMID:16648578
NCBI chr14:77,696,332...77,705,715
Ensembl chr14:77,696,333...77,705,741
G
Zbtb16
zinc finger and BTB domain containing 16
increases expression
EXP
bexarotene results in increased expression of ZBTB16 mRNA
CTD
PMID:23292798
NCBI chr 8:48,989,376...49,177,011
Ensembl chr 8:48,994,566...49,177,011
G
Zp3
zona pellucida glycoprotein 3
increases expression
EXP
bexarotene results in increased expression of ZP3 mRNA
CTD
PMID:16648578
NCBI chr12:20,690,547...20,697,513
Ensembl chr12:20,690,547...20,697,513
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all